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 ABSTRACT 30 
Escherichia coli is one of the most-studied microorganisms worldwide but its 31 
characteristics are continually changing. Extraintestinal E. coli infections, such as 32 
urinary tract infections and neonatal sepsis, represent a huge public health problem. 33 
They are caused mainly by specialized extraintestinal pathogenic E. coli (ExPEC) 34 
strains that can innocuously colonize human hosts but can also cause disease upon 35 
entering a normally sterile body site. The virulence capability of such strains is 36 
determined by a combination of distinctive accessory traits, called virulence factors, in 37 
conjunction with their distinctive phylogenetic background. It is conceivable that by 38 
developing interventions against the most successful ExPEC lineages or their key 39 
virulence/colonization factors the associated burden of disease and health care costs 40 
could foreseeably be reduced in the future. On the other hand, one important problem 41 
worldwide is the increase of antimicrobial resistance shown by bacteria. As underscored 42 
in the last WHO global report, within a wide range of infectious agents including E. 43 
coli, antimicrobial resistance has reached an extremely worrisome situation that 44 
“threatens the achievements of modern medicine”. In the present review, an update of 45 
the knowledge about the pathogenicity, antimicrobial resistance and clinical aspects of 46 
this “old friend” was presented. 47 
 48 
 49 
 50 
 51 
 52 
 53 
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INTRODUCTION 54 
Escherichia coli is the most-studied microorganism. It is both a common commensal 55 
inhabitant of the gastrointestinal tract and one of the most important pathogens in 56 
humans. Thus, the most frequent cause of bloodstream infection and urinary tract 57 
infections (UTIs) among Gram-negative bacteria is E. coli. Such isolates possess 58 
specialized virulence factors such as adhesins, toxins, iron-acquisition systems, 59 
polysaccharide coats and invasins that are not present in commensal and intestinal 60 
pathogenic strains (Sannes 2004). In addition, E. coli are the enteric Gram-negative 61 
bacilli most frequently found in the genital tract of women, causing vaginal and/or 62 
endocervical colonization as well as different infections in pregnant women,  such as 63 
intra-amniotic and puerperal infection, and neonatal infections, such as early and late 64 
neonatal sepsis (Guiral 2011). 65 
Antimicrobial resistance in E. coli is consistently highest for antimicrobial agents that 66 
have been in use the longest time in human and veterinary medicine, such as ampicillin. 67 
However, in the past two decades increases have been observed in the emergence and 68 
spread of multidrug-resistant bacteria, including strains resistant to newer antibiotics 69 
such as fluoroquinolones and extended-spectrum cephalosporins (Levy 2004). 70 
An update of the clinical aspects, pathogenesis and antimicrobial resistance of E. coli is 71 
compiled in this review.  72 
 73 
74 
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PATHOGENESIS OF Escherichia coli 75 
Extraintestinal Escherichia coli  76 
E. coli is an extremely common and complex human pathogen. It is the most frequently 77 
isolated species in clinical microbiology laboratories and is the leading cause of UTIs, 78 
with millions of cases and billions of dollars in associated health care costs annually in 79 
the U.S. (Russo 2004). Although E. coli is most closely linked to UTI, it can infect any 80 
extraintestinal site, causing meningitis, skin structure infections, myositis, osteomyelitis, 81 
and epididymo-orchitis. Severe E. coli infections, which often involve bloodstream 82 
infection (of which E. coli is a leading cause), frequently result in the systemic 83 
inflammatory response syndrome (SIRS), contributing to an estimated 40,000 deaths 84 
annually in the U.S. (Russo 2004). This major burden of morbidity, mortality, and costs 85 
greatly exceeds that associated with diarrheagenic E. coli, which in contrast receive 86 
much more attention from the press, public health system, and lay public.  87 
E. coli is a diverse species which, from a human health perspective, can be viewed as 88 
comprising three main subsets (Touchon 2009; Johnson 2002b). Commensal strains 89 
innocuously colonize the colon of healthy hosts, causing extraintestinal disease only in 90 
the presence of a large inoculum (e.g., with penetrating abdominal trauma) and/or 91 
significant host compromise. Diarrhoeagenic strains cause diarrhoea syndromes that 92 
vary in clinical presentation and pathogenesis according to the strain's distinctive 93 
virulence traits. These differences serve as the basis for the classifying the strains into 94 
sub-pathotypes, e.g., enterohemorrhagic E. coli (EHEC), enterotoxigenic E. coli 95 
(ETEC), and enteropathogenic E. coli (EPEC) and enteroaggregative E. coli (EAEC). 96 
Such strains almost never cause extraintestinal infection and, outside the developing 97 
world, rarely colonize healthy hosts. Finally, like commensal strains, extraintestinal 98 
pathogenic E. coli (ExPEC) often innocuously colonize the human gut. However, they 99 
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have a unique ability to enter and survive within normally sterile extraintestinal body 100 
sites, and to cause disease when they do so. ExPEC strains are the main cause of human 101 
extraintestinal E. coli infections. Although traditionally designated as uropathogenic E. 102 
coli (UPEC) because of their association with UTI, such strains are now recognized as 103 
being more broadly pathogenic, leading to widespread use of the more inclusive term 104 
ExPEC (Russo 2000). 105 
The three main E. coli clinical subsets, or pathotypes (commensal, diarrhoeagenic, and 106 
ExPEC), can be distinguished by comparative genome analysis. Although sharing a set 107 
of genes that is common to all E. coli, i.e., the E. coli core genome, the three pathotypes 108 
differ according to the presence/absence of multiple so-called accessory traits, which are 109 
dispensable for vegetative growth but determine the strains' distinctive clinical 110 
behaviors. The three pathotypes also tend to segregate within the phylogenetic tree of E. 111 
coli, with ExPEC occurring mainly in groups B2 and D, and commensal and 112 
diarrhoeagenic strains in other groups (Touchon 2009). However, certain non-group 113 
B2/D strains and clonal groups have acquired sufficient relevant accessory traits 114 
(probably via horizontal gene transfer) to become ExPEC (Johnson 2001). Conversely, 115 
some group B2/D strains that exhibit ExPEC-like characteristics also exhibit 116 
characteristics that define the diarrheagenic pathotypes known as adherent and invasive 117 
E. coli (AIEC) and enteroaggregative E. coli (EAEC) (Olesen 2014; Nash 2010; 118 
Vejborg 2011), which are discussed in greater detail in separate sections below. Despite 119 
the many genetic similarities between AIEC and ExPEC, the latter do not exhibit the 120 
adherent-invasive phenotype of AIEC (Martinez-Medina 2009a). This fact indicates that 121 
additional ‘virulence’ factors conferring better fitness for colonization, and resistance to 122 
unfavorable conditions, may be implicated in the AIEC phenotype. It is still unknown 123 
whether particular unidentified genes or mutations of certain genes present in all AIEC 124 
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are responsible for the AIEC phenotype, or to the contrary, if changes in different genes 125 
may lead to the same phenotype, and thus, AIEC might have emerged several times 126 
from different phylotypes. Genome sequencing of four AIEC has revealed some specific 127 
genes for AIEC, however these strains belong to the same B2 phylogroup (Clarke 128 
2011). Given the high diversity of seropathotypes among AIEC, it is crucial to analyze 129 
several isolates of different phylogenetic origin in order to unravel the genetic basis of 130 
the AIEC phenotype. Additionally, it would be of interest to analyze for differences 131 
between AIEC and non-AIEC at the level of gene expression or to reveal the presence 132 
of point mutations, since isolates that are genomically very similar may differ in the 133 
AIEC phenotype (Martinez-Medina 2009). 134 
The specialized traits that distinguish ExPEC strains from other E. coli subserve 135 
functions that promote survival on or in the host, including through attachment, nutrient 136 
acquisition, competition with other bacteria, and avoidance or subversion of host 137 
defense mechanisms, and/or lead to host cellular or tissue injury and, hence, disease 138 
(Johnson 2005). Although such traits traditionally have been regarded as "virulence 139 
factors", many of them are increasingly considered as being "fitness factors" that can 140 
promote colonization (including of the intestine) without leading to disease.  141 
ExPEC strains tend to have multiple virulence factors, including multiple 142 
representatives of a given functional category (Johnson 2005; see UPEC section as 143 
example). Many different combinations of virulence factors occur in different ExPEC 144 
strains, evidence that there are many pathways to extraintestinal virulence in E. coli. 145 
Although virulence factor profiles tend to be fairly lineage-specific, consistent with 146 
vertical inheritance, variations in profiles are common even with a given lineage, 147 
consistent with horizontal gene transfer or deletions. Horizontal transfer involving 148 
virulence factor-encoding genes can occur via plasmids, phage-mediated transduction, 149 
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or other forms of recombination, and often involves blocks of DNA called "fitness 150 
islands" or "pathogenicity-associated islands" that contain multiple known or suspected 151 
virulence genes (Hacker 2001; see specific section in this review). Analysis of genes of 152 
unknown function that are encountered adjacent to known virulence genes within such 153 
islands  can lead to the discovery of novel virulence genes (Swenson 1996). 154 
Three main approaches can be used to determine whether a given E. coli isolate is 155 
ExPEC. The simplest and most widely used, albeit least reliable, uses clinical context 156 
and source of isolation to indicate the strain's virulence potential. Here, all clinical E. 157 
coli isolates from sites of extraintestinal infection are regarded as ExPEC and all 158 
colonizing isolates (e.g., in feces) are regarded as non-ExPEC (Sannes 2004). However, 159 
this logic is flawed, since compromised hosts can develop serious infections due to low-160 
virulence organisms (Johnson 1998), and the gut is an important reservoir for the E. coli 161 
strains that cause serious extraintestinal infections in otherwise healthy hosts (i.e., 162 
presumptive ExPEC) (Yamamoto 1997).  163 
A more reliable approach is to characterize the isolate for phylogenetic background and 164 
virulence factor profile, which allows inferences regarding the isolate's likely virulence 165 
potential. This approach also has limitations, since the correspondence between these 166 
bacterial characteristics and actual virulence is incompletely defined, and not all 167 
relevant traits have been identified or can be readily tested for.  168 
A more direct approach, which requires no prior knowledge of the isolate's source or 169 
molecular characteristics, is to challenge animals with the isolate in an experimental 170 
infection model, and to observe disease outcomes (Hagberg 1983; Johnson 2006). 171 
Although this approach also has limitations, including being unsuitable for routine or 172 
large-scale use and the uncertain reliability of animal models for mimicking human 173 
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disease, it provides the most direct assessment of an isolate's virulence potential, and is 174 
useful for testing specific bacterial traits as possible virulence factors (Falkow 1988). 175 
Despite the considerable diversity of ExPEC strains, they are actually much less diverse 176 
than is the E. coli species as a whole, and they tend to be dominated by certain high-177 
prevalence (i.e., frequently encountered) lineages, which traditionally have been called 178 
"virulent clones" (Bonacorsi 2003; Achtman 1986; Johnson 2002b). The basis for the 179 
epidemiological success of these dominant ExPEC lineages, which implies enhanced 180 
fitness in some niche compared to other E. coli, is an area of active investigation. 181 
Explanations proposed for these lineages' success include enhanced host-to-host 182 
transmission, gut colonization, virulence, and antimicrobial resistance (Banerjee 2014). 183 
Notably, certain observational and experimental data suggest that specific bacterial 184 
traits may enhance fitness in multiple such domains. For example, in household 185 
colonization studies the most widely shared strains (such as intestinal or vaginal 186 
colonizers) tend to be those with the most virulence genes, those from phylogenetic 187 
group B2, and those that caused UTI in one or more household members (Johnson 188 
2008). Likewise, in experimental systems certain traits classically regarded as virulence 189 
factors (e.g., P fimbriae and group 2 capsule) contribute to gut colonization, suggesting 190 
that they may also be colonization factors (Herías 1995; Herías 1997), which is most 191 
likely the true evolutionary basis for their selection and retention.  192 
 193 
Pathogenesis of Neonatal Sepsis by Escherichia coli 194 
Neonatal sepsis is an important but underestimated problem around the world. Neonatal 195 
sepsis is defined as disease affecting newborns ≤ 1 month of age with clinical symptoms 196 
and positive blood cultures. The incidence of this disease is 1/1000 in normal term 197 
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neonates and 4/1000 in preterm neonates, increasing up to 300/1000 in low weight 198 
neonates. Sepsis by bacterial infection is one of the most important causes of morbidity 199 
and mortality in newborns in both developed and developing countries (Stoll 2011). 200 
Many of these bacterial pathogens can frequently be found colonizing the vagina, cervix 201 
or rectum of pregnant adult women. Such pathogens may reach the fetus during the late 202 
stages of pregnancy by crossing the amniotic membrane or by directly infecting the 203 
baby during childbirth (Romero 1988). In the case of early neonatal sepsis (by 204 
intrauterine or congenital transmission through the placenta) secondary to bacteria, 205 
these microorganisms could arise from a prematurely ruptured amniotic membrane 206 
which becomes infected, genuinely infected amniotic liquid (chorioamnionitis), or 207 
preterm delivery in a mother colonized by such bacteria, who may have a much higher 208 
risk of infecting her offspring due to the immaturity of the neonate’s immune system. 209 
Preterm delivery constitutes 5-10% of pregnancies and its occurrence has previously 210 
been linked to infection in the genital tract of women during pregnancy (McGregor 211 
1996; Gravett 2000; Stoll 2002). On the other hand, late-onset neonatal sepsis is defined 212 
as infection presented four or more days after birth and is commonly caused by 213 
microorganisms acquired from the environment rather than from the mother. 214 
Ascending infection can be described in four main steps: i) The presence of bacteria in 215 
the vagina/cervix; ii) The bacteria resides in the decidua; iii) The bacteria colonizes the 216 
amnion or the chorion, going through the fetal vessels or crossing the amnion, reaching 217 
the amniotic cavity; and iv) The bacteria enters the fetus through the infected amniotic 218 
liquid and reaches the blood. 219 
Neonatal sepsis can be subdivided into: i) Early-onset neonatal sepsis (EONS): The 220 
microorganisms most frequently found to cause of EONS are group B streptococcus 221 
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(GBS) and E. coli, followed by coagulase-negative staphylococcus, Listeria 222 
monocytogenes and Haemophilus influenzae. Maternal GBS colonization, premature 223 
and/or prolonged rupture of membranes, prematurity, maternal urinary tract infection, 224 
and chorioamnionitis, among others, are considered as risk factors associated with 225 
EONS. 226 
ii) Late-onset neonatal sepsis (LONS): In contrast to EONS, there is a wide variety of 227 
microorganisms associated with LONS, including coagulase-negative Staphylococcus, 228 
Staphylococcus aureus, E. coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, 229 
Enterobacter cloacae, Candida spp. and GBS. The risk factors associated with LONS 230 
are also different from those associated with EONS and include prematurity, central 231 
venous catheterization (more than 10 days), nasal cannula or continuous positive airway 232 
pressure use, gastrointestinal tract pathology, exposure to antibiotics and prolonged 233 
hospitalization, among others. 234 
Treatment of neonatal sepsis consists in ampicillin plus an aminoglycoside, usually 235 
gentamicin. Other antimicrobials used are cefotaxime, vancomycin, metronidazole, and 236 
piperacillin. The choice of the antibiotic depends on the microorganism associated with 237 
sepsis, the susceptibility of the bacterial pathogen, and the prevailing nosocomial 238 
infection trends in the nursery.  239 
To avoid enhanced risk of vertical transmission, several diagnostic and prophylactic 240 
protocols have been proposed. In 2002 the Center of Disease Control (CDC) 241 
recommended taking vaginal and rectal samples from pregnant women in their last 242 
antenatal visit and administering a prophylactic antibiotic such as penicillin G or 243 
ampicillin during pregnancy or at the time of delivery in women found to be colonized 244 
by GBS in antenatal screenings (Raymond 2008). The use of these prophylactic 245 
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measures resulted in a decrease in the incidence of infection by GBS (cdc.gov). A good 246 
example of this success was a study carried out in 10 hospitals of Barcelona (Spain) in 247 
which it was found that the incidence of GBS as a cause of neonatal sepsis was reduced 248 
from 1.92/1,000 newborns in 1994 to 0.26/1,000 newborns in 2001 (p <0.001).  249 
However, several studies have suggested that these prophylactic measures could lead to 250 
a possible increase in the presence of other microorganisms such as E. coli (Schrag 251 
2006; Sgro 2011; Lin 2011), and an increase in antimicrobial resistance, and the 252 
selection of resistant microorganisms.  253 
Examples of the increase of E. coli after the implementation of the intrapartum 254 
prophylaxis are shown in Table 1. 255 
Several studies have also related this increase of E. coli to preterm labor, the 256 
prophylaxis given, maternal urinary tract infection by E. coli and active in-utero 257 
infection associated with the rupture of membranes and concluded that the antimicrobial 258 
treatment increases the risk of maternal colonization with antibiotic-resistant organisms 259 
(Jones 2004; Bizzarro 2008).   260 
High rates of resistance to ampicillin and gentamicin among E. coli causing neonatal 261 
sepsis have been reported worldwide (Thaver 2009; Amaya 2010; Heideking 2013). A 262 
good example of the increase of these resistances has been described in Spain from 263 
1998 to 2008 by Guiral et al. (2012), who reported a rise in ampicillin and gentamicin 264 
resistance from 56% to 78%, and 0% to 26%, respectively. 265 
The increase observed in the resistance to these antibiotics selected as empirical 266 
treatment could be caused by the selection of resistant strains due to exposure to 267 
antibiotics, making a change in the treatment of neonates necessary. However, further 268 
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studies are needed to elucidate the role of intrapartum antibiotic prophylaxis in the 269 
emergence of resistant strains. 270 
Another important feature of E. coli is its virulence. This microorganism presents 271 
several virulence factors that favor their capacity to cause sepsis. Among these factors, 272 
capsule, LPS, fimbriae, toxins, etc. may have a role in this type of infection. 273 
Studies on the virulence of E. coli causing neonatal sepsis are scarce (Watt 2003). In 274 
this sense, IbeA has been proposed as a virulence factor that could play an important 275 
role in the translocation of E. coli through the amniotic membrane (Soto 2008). The 276 
gene encoding this protein is located in the pathogenicity island GimA that contributes 277 
to the invasion of the blood-brain barrier through a carbon-regulated process. Studies 278 
carried out in our laboratory hav  shown that two E. coli toxins could also be involved 279 
in the translocation through the amniotic membrane and in the development of neonatal 280 
sepsis (Sáez-López et al., unpublished data). 281 
However, when a high degree of bacteremia occurs, E. coli can successfully crossing 282 
the blood-brain barrier previous binding and invasion of the human brain microvascular 283 
endothelial cells (HBMECs) (Kim 2008), causing central nervous system (CNS) 284 
inflammation resulting in neonatal meningitis.  285 
E. coli is the second cause of neonatal meningitis leading high rates of mortality (20-286 
29%) and morbidity among neonates, being its incidence about 0.1/1000 live births 287 
among industrialized countries (Bonacorsi 2005). The high prevalence of these 288 
infections occurs in the neonatal period (< 28 days of life), and only about 10% occur 289 
between 1-3 months of age (Unhanand 1993; Okike 2014). As consequence of this 290 
infection, an important of neonates develops neurological damages being more frequent 291 
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when the meningitis is accompanied by ventriculitis or intracerebral abscess 292 
(Dellagrammaticas 2000). 293 
Development of neonatal meningitis by E. coli comprises three steps: i) translocation 294 
from the intestine lumen to the bloodstream (but also from urinary tract or the utero); ii) 295 
intravascular survival and multiplication; and iii) passage of the bacteria through the 296 
blood-cerebrospinal-fluid barrier (CSF) and invasion of the arachnoidal space 297 
(Bonacorsi 2005; Kim 2012).  298 
About 80% of the E. coli strains causing meningitis belong to capsular serotype K1, 299 
being the serotypes O18:K1 and O7:K1 the most frequently found (about 50% of all 300 
K1) (Achtman 1983; Moulin-Schouleur 2006). The VFs found to be associated with the 301 
ability of these E. coli strains to cause neonatal meningitis are related to outer 302 
membrane proteins (capsular antigen K1, OmpA protein), siderophores (iroN, fyuA, and 303 
iucC/iutA genes), adhesins (P-fimbriae, S-fimbriae, and type-1-fimbriae), and invasion 304 
(ibeA, asl and cnf1 genes) (Xie 2004). In addition, successful invasion of HBMEC also 305 
requires HBMEC actin cytoskeleton rearrangement and activation of several host 306 
factors or related signalling molecules such as focal adhesion kinase (FAK), paxillin 307 
and phosphatidylinositol 3-kinase (PI3-K), PhoGTPases and cytosolic phospholipase 308 
A2 (cPLA2) (Khan 2002). 309 
In summary, E. coli has replaced GBS as a cause of neonatal sepsis and 310 
meningitis in many countries in which the CDC guidelines have been implemented. 311 
More than 90% of these E. coli strains are resistant to ampicillin possibly due to 312 
antibiotic prophylaxis. Several virulence genes, including toxins and invasins, seem to 313 
play an important role in the pathogenesis of these infections (adhesion, invasion and 314 
translocation). 315 
Page 15 of 107
ScholarOne Support 1-434/964-4100
FEMS Microbiology Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
15 
 
For these reasons, we think that epidemiological surveillance, in terms of resistance and 316 
etiology, of E. coli causing neonatal infections is needed. 317 
 318 
Biofilm Formation of Escherichia coli Isolates 319 
Biofilm formation is the capability of the microorganisms to self-organize into 320 
multicellular communities embedded in a mainly self-produced, extracellular matrix 321 
directed through distinct genetic programs (Costerton 1987; Römling 2012). Besides 322 
being the major life style of most microorganisms, biofilm formation is a medical 323 
problem of wide significance. Indeed, biofilm formation is considered both a major 324 
virulence factor of chronic infections due to the inability of the immune system to 325 
eradicate the microorganisms and a clinical problem due to the failure of antibiotics to 326 
successfully eliminate them. In addition, biofilm formation can also play a role in 327 
certain stages of acute infections and is important for transmission of pathogens. The 328 
medical problem of biofilm formation, though, goes far beyond chronic infections as 329 
biofilm associated diseases promote the extensive use of antibiotics and biofilm 330 
formation promotes the spread of antimicrobial resistance (Soerensen 2005). The 331 
spectrum of UTIs, catheter-associated UTIs, acute and recurrent UTIs, cystitis and 332 
pyelonephritis, but also inflammatory bowel diseases such as Crohn’s disease are 333 
classical examples of diseases in which biofilm formation of E. coli to disease 334 
contribution was suspected and investigated early (Anderson 2003; Darfeuille-Michaud 335 
2004; Wang 2010; see specific section in this review).  336 
Biofilm formation of commensal strains and pathovars of E. coli is largely unexplored 337 
considering the vast number of mainly functionally uncharacterized fimbriae as well as 338 
confirmed and potential exopolysaccharide operons (Korea 2010) as well as the vast 339 
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number of horizontally transfered genomic information adding additional proven and 340 
suggested adherence and biofilm factors (see below, Pathogenicity islands) (Ghigo 341 
2001; Ong 2009);  342 
Rdar biofilm formation, a biofilm displayed by a distinct colony morphology type, was 343 
characterized in commensal and uropathogenic strains of E. coli has been characterized 344 
(Bokranz 2005; Kai-Larsen 2010). Rdar biofilm is a multicellular biofilm behavior 345 
characterized by the expression of the extracellular matrix components curli fimbriae 346 
and cellulose (Bokranz 2005). The major hub of rdar biofilm regulation is the 347 
transcriptional regulator CsgD. Commensal isolates and E. coli pathovars have been 348 
reported to express the rdar morphotype under laboratory conditions, but a clear 349 
association of an rdar expression pattern with a certain E. coli pathovar or disease 350 
condition has not yet crystallized. Interestingly, however, a recent study demonstrated 351 
that most E. coli O157:H7 strains show impaired rdar biofilm formation due to 352 
impairment of major transcriptional regulators RpoS and/or MlrA of the rdar 353 
morphotype (Uhlich 2013). Another noteworthy observation is that isolates of the 354 
probiotic E. coli strain Nissle 1917 have maintained their conserved rdar morphotype 355 
regulatory pattern with CsgD independent cellulose expression at 37°C for over almost 356 
100 years in nature (Figure 1) (Kleta 2006; Monteiro 2009).  357 
Rdar morphotype expression significantly changes the interaction of E. coli with the 358 
host. Remarkably therefore, the extracellular matrix components curli fimbriae and the 359 
exopolysaccharide cellulose often have the opposite effect on microbial host interaction 360 
in not only a cell culture model, but also in an animal model of UTI (Wang 2006; 361 
Monteiro 2009; Kai-Larsen 2010; Lamprokostopoulou 2010). For example, while the 362 
amyloid curli fimbriae promote adhesion and invasion of commensal and pathogenic E. 363 
coli strains into host cells and stimulate secretion of the proinflammatory cytokine 364 
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interleukin-8, (co-)expression of cellulose inhibits this process (Wang 2006; Saldaña 365 
2009; Kai-Larsen 2010). Again E. coli strain Nissle 1917 is an exception as cellulose 366 
promotes adherence and IL-8 production, and only slightly inhibits invasion (Monteiro 367 
2009).  368 
Interestingly, rdar morphotype components also have an impact on an animal model of 369 
UTI since expression of curli fimbriae, but not cellulose or both components, enhances 370 
the recovery from the kidney in the early infection phase (Kai-Larsen 2010). One reason 371 
might be the enhanced resistance of curli-expressing cells against the antimicrobial 372 
peptide LL-37, a phenotype that extends the survival of curli-expressing cells of the 373 
bladder epithelial cell line T24. In addition, expression of the macrophage inflammatory 374 
protein 2 (MIP-2) chemokine is highly enhanced upon infection of curli-producing 375 
bacteria, while cellulose-expressing strains virtually show no MIP-2 induction 376 
compared to uninocculated controls. Later in infection, however, only curli fimbriae-377 
expressing cells are eliminated faster. This elimination is mediated by neutrophils as in 378 
neutrophil depleted animals curli fimbriae-expressing cells are maintained at equal 379 
numbers to those of the wild type strain. Although curli have been found to be 380 
expressed in human urine suggesting a contribution of the rdar biofilm to human UTI 381 
infection (Kai-Larsen 2010), initial adherence of E. coli to catheter surfaces seems to be 382 
independent of csgD (Figure 2) (Wang , unpublished results). Adding to the complexity 383 
of biofilm mediated bacterial host phenotypes, cellulose has recently also been 384 
identified as an inflammation inducing component of an adherent-invasive E. coli strain 385 
in a mouse model of colitis (Ellermann 2015). Interesting, when investigating the 386 
interaction of AIEC strain NC 101 with macrophages, an opposite effect of cellulose 387 
production in interaction with macrophages with respect to phagocytosis and production 388 
of the proinflammatory cytokine IL12 p40 dependent on iron availability was observed. 389 
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Nevertheless, expression of the rdar morphotype is highly regulated by E. coli “ex vivo” 390 
and “in vivo”. A major regulator of rdar biofilm formation in E. coli, the closely related 391 
S. Typhimurium and other bacteria is the ubiquitous bacterial secondary messenger 392 
cyclic di-GMP (Schirmer 2009; Sondermann 2012; Römling 2005; 2006; 2013; Hengge 393 
2015). Cyclic di-GMP, originally identified as the allosteric regulator of cellulose 394 
synthase in 1987 (Ross 1987), was rediscovered in 2004 as an ubiquitous secondary 395 
messenger regulating the ;transition between the motile and sessile life style of 396 
microbes (Simm 2004; Paul 2004; Tischler 2004). A short time thereafter, transition 397 
between chronic infection and the acute virulence phenotype was also identified as an 398 
ubiquitous characteristic regulatory pattern of the cyclic di-GMP signaling system.  399 
The cyclic di-GMP signaling system is the most complex secondary messenger network 400 
of bacteria. In E. coli, this signaling system is of moderate complexity with about 31 401 
cyclic di-GMP turnover proteins (Sommerfeldt 2009; Römling 2005). In line with the 402 
overall phenotype of biofilm producing E. coli, adherence, invasion and production of 403 
proinflammatory cytokines have been demonstrated to be regulated by the cyclic di-404 
GMP signaling system by turnover proteins with unique or partially redundant function 405 
(Hu 2009; Spurbeck 2013). In the uropathogenic strain E. coli CFT073 dysregulation of 406 
the di-guanylate cyclase YfiN by deletion of the periplasmic negative regulator YfiR 407 
upregulated the rdar morphotype (Raterman 2013). Concomitant with upregulation of 408 
the rdar morphotype, the cell number in the bladder and kidney was reduced. Reduction 409 
could be relieved by deletion of the cellulose synthase and the biofilm regulator CsgD. 410 
Albeit preliminary, these studies point to a central role of the cyclic di-GMP signaling 411 
system in the transition between virulence and biofilm formation (Römling 2013).  412 
In summary, we can conclude that biofilm formation in E. coli is highly prevalent, but 413 
also variable. In spite of the diverse studies on E. coli biofilms even beyond the rdar 414 
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morphotype (Rendón 2007; Itoh 2008; Lasaro 2009; Steiner 2013; Yakovenko 2015; 415 
Staerk 2016)), several major questions remain unanswered. What are the evolutionary 416 
forces in commensalism and disease, and also outside the human body, which shape its 417 
regulation? We have discovered very few biofilm phenotypes so far; can we define 418 
additional ones and the circumstances, under which they are required? Cyclic di-GMP 419 
signaling is a major regulator of biofilm-motility and biofilm-virulence transition in E. 420 
coli; can we define specific cyclic di-GMP metabolizing enzymes involved in biofilm 421 
and virulence regulation? Very few phenotypes mediated by cyclic di-GMP signaling 422 
have been identified; can we define additional phenotypes regulated by cyclic di-GMP 423 
signaling? Biofilm formation and cyclic di-GMP signaling generally inhibit acute 424 
virulence phenotypes; we know very little about the contribution of biofilm formation 425 
and cyclic di-GMP signaling to chronic infection phenotypes. And last, but not least, 426 
what is the contribution of biofilm formation and cyclic di-GMP signaling to 427 
antimicrobial resistance phenotypes in E. coli? 428 
 429 
Pathogenicity-associated islands (PAIs): implications for the pathophysiology, 430 
epidemiology and diagnosis of Escherichia coli 431 
The species E. coli are characterized by a remarkable genomic diversity. Comparative 432 
genomics has furthered our understanding of bacterial diversity, the characteristics of 433 
populations and has demonstrated that E. coli genomes consist of a conserved, so-called 434 
core genome and a flexible part. The flexible gene pool codes for properties that 435 
contribute to the bacterial adaptability and fitness. It is represented by (former) mobile 436 
genetic elements including bacteriophages, plasmids, insertion sequence (IS) elements, 437 
(conjugative) transposons and integrons as well as non-functional fragments of these 438 
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genetic elements (Ochman 2000; Touchon 2009; Chaudhuri 2012; Toussaint 2012). The 439 
term pathogenicity island (PAI) defines large genomic regions that are present in 440 
pathogenic but are absent in non-pathogenic strains and harbor pathogenicity-related 441 
genes. Such elements are commonly inserted into tRNA genes; their G+C content and 442 
codon usage is distinct from that of the core genome, and they are often unstable 443 
(Hacker 2001; Schmidt 2004; Gal-Mor 2006). The ever increasing amount of DNA 444 
sequencing data resulted in a more generalized view of such genetic entities belonging 445 
to the flexible gene pool and denoted PAIs as a subtype of 'genomic islands' (GEIs) 446 
(Blum 1994; Hacker 2002; Hacker 2003; Dobrindt 2004). GEIs generally represent a 447 
characteristic feature of E. coli and they play an important role in the evolution of 448 
different variants or pathotypes. A considerable fraction (up to 30 %) of the entire E. 449 
coli genome is represented by GEIs and PAIs. Accordingly, pathogenicity-associated 450 
genes located on PAIs or even complete islands, e.g. the 'locus of enterocyte effacement' 451 
(LEE), frequently serves as biomarkers for individual E. coli pathotypes. 452 
Comparative analysis of PAIs and GEIs revealed the dynamics of genomes within a 453 
single species, including INDELs (INsertion/DELetions), acquisition of genes and gene 454 
clusters through horizontal gene transfer, and genomic rearrangements, in addition to 455 
sequence variation within single genes, differences in regulatory sites, and SNPs that 456 
may lead to functional diversity.  457 
The comparison of PAIs in different E. coli strains indicated that identical or almost 458 
identical PAIs can exist in different E. coli pathotypes or strains (Dobrindt 2004; 459 
Brzuszkiewicz 2009; Chaudhuri 2012; Leimbach 2013). Typical examples are the 'high 460 
pathogenicity island' (HPI) or the LEE PAI. Nevertheless, many PAIs exhibit a mosaic-461 
like, modular structure, i.e. they do not consist of a contiguous stretch of horizontally 462 
acquired DNA, but comprise DNA fragments of different origin. These different mobile 463 
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genetic elements and horizontally transferred DNA regions have been acquired by 464 
independent events in the course of evolution (Hacker 2000; Touchon 2009; Schubert 465 
2009). Although these PAIs exhibit an overall similar genetic structure and gene 466 
content, there is a great variability regarding their composition and chromosomal 467 
localization even within one particular patho- or serotype. Basically functional and 468 
structurally unrelated islands can include a multitude of redundant DNA regions, which 469 
have been accumulated by repeated integration and partial deletion of mobile and 470 
accessory elements. These multiple copies of identical or very similar DNA sequences 471 
can promote homologous recombination within an island or between different 472 
horizontally acquired DNA elements and thus cause DNA rearrangements, deletions or 473 
the incorporation of foreign DNA. Accordingly, a multitude of functionally identical, 474 
but structurally variable PAIs can be found in the genomes of pathogenic E. coli 475 
isolates. In order to characterize or identify PAIs in clinical isolates, many laboratories 476 
screen for a few selected marker genes from known islands. Against the background 477 
described above, this approach may cause the problem that the detection of a limited set 478 
of virulence markers may not indicate the presence of one particular entire PAI of a 479 
reference strain. 480 
The modular composition of functionally related PAIs in different E. coli strains can be 481 
exemplified by related PAIs of ExPEC carrying the salmochelin determinant (iro). The 482 
iro gene cluster is often associated with genes coding for the Salmonella iron transport 483 
(sit) determinant as well as with colicin and adhesin determinants (Dobrindt 2002; 484 
Startic Erjavec 2003; Brzuszkiewincz 2009). Variable regions between these genes 485 
often represent repetitive sequences or IS elements. Interestingly, many of these 486 
determinants located on this type of ExPEC PAI can also be found on islands and large 487 
virulence plasmids present in related species, e.g. Salmonella spp., Shigella spp. or K. 488 
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pneumoniae (Brzuszkiewincz 2009), corroborating the transfer and exchange of 489 
individual modules of these PAIs or plasmids. The interrelation between PAIs and 490 
integrative and conjugative elements (ICEs) and plasmids is clearly visible when, for 491 
example, the HPI in association with the colibactin-encoding PAIs of uropathogenic E. 492 
coli and Citrobacter koseri BAA-895 are compared with ICEEc1, ICEKp1 and the 493 
multiresistance plasmid pMET1 of K. pneumoniae and the Yersinia pestis plasmid 494 
pCRY (Schubert 2004; Lin 2008; Soler Bistué 2008; Putze 2009). 495 
Many IS elements, genes encoding integrases or non-functional gene fragments are part 496 
of PAIs and GEIs (Brzuszkiewincz 2006; Putze 2009). The fact that several 497 
pathogenicity-related determinants can be localized on different types of mobile genetic 498 
elements underlines the involvement of conjugative transposons, ICEs, bacteriophages 499 
and plasmids in the evolution and ongoing further shaping of PAIs and GEIs (Dobrindt 500 
2004; Ahmed 2008). 501 
Horizontal gene transfer is important for the rapid introduction and spread of new 502 
genetic determinants, including virulence genes. PAIs, bacteriophages, conjugative 503 
plasmids, conjugative transposons, ICEs and natural transformation are well known 504 
vehicles that can promote interspecies gene transfer, but the conditions for and the 505 
frequency of transfer events in the natural environment are not well understood. PAIs or 506 
GEIs can be transferred to suitable recipients either by helper phage or as integrative 507 
and conjugative elements (ICEs) (Schubert 2004; Schneider 2011; Soto 2011). They can 508 
also have the intrinsic ability to be horizontally transferred (Lesic 2004). 509 
The presence of a functional bacteriophage-like integrase gene and flanking repeat 510 
structures is an important requirement for the excision of PAIs; a prerequisite for their 511 
dissemination by horizontal transfer (Hacker 2000; Schmidt 2004). PAI-encoded 512 
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integrases are required for site-specific recombination and the excision of their cognate 513 
PAI. In addition, RecA-dependent homologous recombination can be responsible for an 514 
alternative method of PAI excision due to the presence of multiple copies of similar IS 515 
elements and other repetitive DNA sequences. As these accessory genetic elements can 516 
insert into the bacterial chromosome without extensive sequence homology at different 517 
genomic localizations, homologous recombination between them accidentally results in 518 
complete or partial excision of PAIs.  519 
Deletion of PAIs can occur in different enterobacterial isolates including E. coli with 520 
frequencies ranging from 10-4 to 10-6 (Rajakumar 1997; Tauschek 2002; Middendorf 521 
2004; Lesic 2004). Interestingly, the deletion frequency depends in part on individual 522 
growth conditions. There are also indications that the PAI excision rate is directly 523 
correlated with the length and integrity of the flanking repeat structures. Furthermore, 524 
the availability of nucleoid-associated proteins and the chromosomal localization of 525 
PAIs can affect site-specific recombination as well as the expression of PAI-encoded 526 
integrases (Hochhut 2006). Nucleoid-associated protein variants are often encoded on 527 
mobile genetic elements including PAIs, thus increasing the possibilities of differential 528 
regulation of genes located on these horizontally transferred genetic elements 529 
(Williamson 2005; Müller 2010; Levine 2014). 530 
Transfer of excised E. coli PAIs in vitro by conjugation has been shown (Schneider 531 
2011). If and under which conditions the acquisition or deletion of PAIs or fragments 532 
thereof is induced or repressed remains to be investigated more in depth. One important 533 
aspect of PAI instability is the mobilization of PAIs, which allows rapid dissemination 534 
of determinants coding for complex traits. Furthermore, E. coli pathogens can quickly 535 
alter their phenotypes by adapting, with the excision or incorporation of PAIs during 536 
pathogen-host interaction. This might be advantageous for example during the transition 537 
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from acute to chronic infections by preventing strong activation of the host immune 538 
response. The loss of PAI fragments during pathogen-host interaction has also been 539 
observed in enterohemorrhagic E. coli (EHEC), in which, the spontaneous deletion of 540 
internal regions of two GEIs in E. coli O157:H7 occurred in vitro and in vivo. These 541 
deletions led to the loss of tellurite resistance (ter) and iha adhesin genes, and the 542 
resulting deletion mutants exhibited a reduced colony size (Bielaszewska 2011). Similar 543 
to the gain or loss of Shiga toxin phages in EHEC during infection (Bielaszewska 2008; 544 
Mellmann 2009), the loss of complete or partial PAIs can result a rapid alteration of the 545 
genomic architecture and bacterial phenotype. This underlines that PAI instability 546 
during infection can not only result in different clinical outcomes, but may also interfere 547 
with proper diagnosis and epidemiology. 548 
 549 
ANTIMICROBIAL RESISTANCE IN Escherichia coli 550 
Resistance and Multidrug Resistance of Escherichia coli Worldwide 551 
Antibiotics are a mainstay of public health and play a key role in improving the health 552 
and well being of people all over the world. However, while antibiotics have been 553 
successful in limiting infectious diseases, their use has exponentially increased leading 554 
to the emergence and spread of antibiotic resistance (AMR). Gram-negative bacteria 555 
(GNB), including E. coli, have emerged as major players in resistance, with multidrug 556 
resistance (MDR) now being relatively common (Nordmann 2011; Dortet 2014). AMR 557 
results in reduced efficacy of antibacterials, making the treatment of patients costly and 558 
difficult, or even impossible (Tzouvelekis 2014). In some cases, resistance extends to 559 
the entire repertoire of the therapeutic agents available (the so-called pan-drug resistant 560 
phenotypes), posing a formidable challenge to the antimicrobial therapy and turning 561 
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back the clock to the pre-antibiotic era (Nordmann 2011; WHO 2014). This is 562 
particularly worrisome in view of the current dearth of new compounds active against 563 
MDR-GNB (Theuretzbacher 2012; Tzouvelekis 2014). 564 
Despite the interest of public health, authorities there are currently increasing 565 
difficulties to obtain sequential data of resistance and multi-drug-resistance from 566 
prospective surveillance studies. Most of the surveillance studies available (e.g. 567 
SMART, SENTRY, TEST or MYSTIC) are sponsored by private pharmaceutical 568 
companies and only involve isolates from specific infections or anatomic locations. 569 
They are mostly focused on the study of specific antibiotics, normally those under 570 
marketing promotion (Hawser 2013; Sader 2014; Renteria 2014). Moreover, data are 571 
partially and fractionally published by geographic areas, period of time or resistance 572 
problems, making it difficult to obtain a broader picture of the current epidemiological 573 
situation. Nonetheless, the general perception of several publications and reports is that 574 
resistant and multi-drug resistant (MDR) E. coli isolates have greatly increased during 575 
the last decades and that these surveillance programs can also be used to detect 576 
emerging resistance mechanisms, not only in developed but also in developing countries 577 
(Hawser 2012a, WHO 2014). Different examples of these mechanisms are the detection 578 
of plasmid AmpC β-lactamase or carbapenemase producing E. coli in geographic areas 579 
with unknown resistance trends (Sheng 2013; WHO 2014).  580 
Due to its particular ecology, E. coli can be considered as a sensor of the current 581 
situation of antimicrobial resistance. This organism has consolidated resistance traits 582 
that appeared many years ago and include TEM-1 β-lactamase or the more recent 583 
extended-spectrum β-lactamases (ESBLs), carbapenemases or plasmid-mediated 584 
quinolone resistance (PMQR) mechanisms. Other mechanisms such as ribosomal 585 
methylases affecting aminoglycoside or plasmid mediated fosfomycin resistance have 586 
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yet to be consolidated (Cantón 2006; Rodríguez-Martínez 2011; Wachino 2012; 587 
D’Andrea 2013), that might occur in association with ESBL and/or carbapenemase 588 
production.  589 
Some of the newer resistance mechanisms have emerged in the so-called high-risk 590 
clones, which facilitate persistence and further dissemination of resistance traits around 591 
the world. This is the case of the B2 O25:H4 ST131 clone harboring IncFII plasmids. It 592 
has been responsible for the dissemination of CTX-M-15 ESBL and is also emerging as 593 
a MDR microorganism (Coque 2008; Banerjee 2014). Its presence is not only confined 594 
to the human compartments but also to the environmental and animal compartment, 595 
both in pets and livestock (Liebana 2013; Rubin 2014). This clone is characterized for 596 
its resistance to fluoroquinolones and expanded-spectrum cephalosporins but has also 597 
been able to recruit carbapenemase g nes (Banerjee 2014; Cai 2014).   598 
In a recent report from the WHO, E. coli has been included in a list of the top nine 599 
microorganisms of international concern causing the most common infections in 600 
different settings: in the community, in hospitals or transmitted through the food chain 601 
(WHO 2014). This report highlighted third generation cephalosporin and/or 602 
fluoroquinolone resistance in urinary tract and blood stream infections that limit empiric 603 
treatments. Figure 3 indicates the highest resistance rates in E. coli isolates published or 604 
reported up to April 2013 in different geographical areas. These data probably reflect 605 
outbreak situations and are much higher than those obtained in antimicrobial 606 
surveillance programs with systematic data collection. As an example, according to the 607 
last report of the European Center for Disease Control (ECDC) on antimicrobial 608 
resistance obtained through the EARS-Net database (EARS-Net), in Europe, resistance 609 
to third generation cephalosporins in invasive isolates, mostly due to ESBL production 610 
has a mean value of 12.6% and ranged from 5.0% in Iceland to nearly 40% in Bulgaria. 611 
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Most of these isolates were also resistant to aminoglycosides and fluoroquinolones and 612 
the mean percentage for combined resistance of third generation cephalosporins, 613 
aminoglycosides and fluoroquinolones was nearly 5%. In general, this percentage was 614 
higher in those countries with higher resistance rates when considering different 615 
antibiotics individually. Interestingly, resistance to carbapenems in Europe was still 616 
only 0.2% in 2013, being higher in Italy (0.6%), Greece (1.4%) and Bulgaria (2.8%) 617 
(EARS-Net). Similar figures for third generation cephalosporin resistance were found in 618 
the SMART study (Figure 4) (Hawser 2012b). 619 
In other geographic areas, such as in China, India or in the Middle East antimicrobial 620 
resistance in E. coli seems to be higher. A recent report of a study characterizing 621 
antimicrobial resistance mechanisms in E. coli in a hospital in China demonstrated the 622 
presence of isolates with multiple resistant genes. These include carbapenemase (blaKPC-623 
2), ESBL (blaCTX-M-3, blaCTX-M-14, blaCTX-M-55), aminoglycoside (aac(6')-Ib, armA and 624 
rmtB) and quinolone (qnrA, qnrB, qnrC, qnrD, qnrS and aac(6')-Ib-cr) resistance genes 625 
(Cai 2014). More importantly, in another study from this country, KPC-2 production 626 
was found to be associated with the high-risk ST131 clone in 40% of the cases (Zhang 627 
2014). Moreover in India, co-production of the carbapenemases NDM-1 and OXA-48 628 
was shown in a large proportion (55%) of the E. coli isolates recovered from UTIs 629 
(Khajuria 2014). This co-production is also common in the Middle East countries 630 
(Zowawi 2014). 631 
In other countries, the emergence and spread of other resistance mechanisms in E. coli 632 
has also been observed. This is the case of fosfomycin resistance which has been largely 633 
described in Korea associated with transferable resistance plasmid harboring fosA 634 
genes. In Hong Kong, the dissemination of fosA3 genes has been observed in diverse E. 635 
coli clones on multiple blaCTX-M-carrying plasmid types. Fosfomycin resistance has also 636 
Fig
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been particularly associated with the production of carbapenemases in European 637 
countries (Kaase 2014). 638 
All these data illustrate the increasing prevalence of E. coli in different parts of the 639 
world and the acquisition of resistance mechanisms in isolates already resistant to other 640 
antimicrobial agents. Very recently WHO has taken the initiative to organize “The 641 
Global Antimicrobial Resistance Surveillance System (GLASS)” that will support the 642 
Global Action Plan on Antimicrobial Resistance with the aims not only to collect 643 
antimicrobial resistance data but also to standardize, compare and validate them. This 644 
initiative will give a worldwide figure of antimicrobial resistance, including that in E. 645 
coli.  646 
 647 
Fluoroquinolone Resistance  648 
Quinolones are a powerful group of antibacterial agents. The first quinolone described 649 
was nalidixic acid, which was discovered by ser ndipity when chloroquine was being 650 
synthetized. Nalidixic acid was a secondary compound in the synthesis of this 651 
antimalarial drug. It showed a narrow spectrum of activity, being active mainly against 652 
Enterobacteriaceae, and was therefore not used much in the clinical setting. However, it 653 
was the initial drug from which other generations of quinolones were developed. The 654 
basic structure of almost all quinolones is based on the 1,4-dihydro-4-oxo-pyridine 655 
molecule. All quinolones have a carboxylic substituent at position 3, which together 656 
with the carbonyl group at position 4, appears to be essential for the activity of the 657 
quinolones. The second generation represented by ciprofloxacin and norfloxacin 658 
presented two main changes with respect to nalidixic acid, the first was a positively 659 
charged group at position 7 (piperazine group in ciprofloxacin) and a fluoride at 660 
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position 6, therefore, since then the new quinolones have been have been called 661 
fluoroquinolones. This generation of quinolones was active against all aerobe Gram-662 
negative bacteria and showed a moderate activity against some Gram-positive bacteria. 663 
The third generation constituted mainly by levofloxacin presented a better activity 664 
against Gram-positive bacteria and finally, in addition to the activity presented by 665 
levofloxacin, the fourth generation showed activity against anaerobes. The 666 
representative of this generation is moxifloxacin (Madurga 2008). 667 
Quinolones inhibit the activity of the DNA gyrase and topoisomerase IV, which belong 668 
to type II topoisomerases and are involved in the topology of DNA. The main function 669 
of the DNA gyrase is to catalyse negative supercoiling of the DNA, thereby playing an 670 
important role in DNA replication and transcription. Meanwhile, the function of 671 
topoisomerase IV is to decatenate int rlinked DNA, thereby playing an important role in 672 
the decatenation of the two daughter molecules of DNA at the end of replication. Both 673 
enzymes show a similar structure consisting in two A subunits and two B subunits.  The 674 
A subunit of the DNA gyrase is encoded by the gyrA gene and the B subunit by the 675 
gyrB gene. To catalyse negative supercoiling, the DNA gyrase performs a transient 676 
double strand break with a passage of another segment of DNA through the break and 677 
later resealing the broken strands. This reaction is catalysed by the A subunit, whereas 678 
the B subunit has ATPase activity and thus hydrolyses ATP to obtain enough energy to 679 
perform the reaction of breakage. Topoisomerase IV also has a structure constituted by 680 
two A subunits and two B subunits. The A subunit is encoded in the parC gene and the 681 
B subunit in the parE gene (Madurga 2008).  682 
Resistance to quinolones has steadily risen over the last decades. Currently, two general 683 
mechanisms of resistance can be found in E. coli; those associated with mutations in the 684 
chromosome and those related to plasmids (Table 2). In this microorganism, mutations 685 
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in the gyrA and parC genes are the most important mechanisms of resistance to 686 
quinolones. Mutations associated with resistance have been mapped in a region called 687 
the quinolone resistance determining region (QRDR). Among these mutations the most 688 
frequently found are those located in the amino acid codons Ser-83 and Asp-87 of the 689 
GyrA and at the amino acid codons Ser-80 and Glu-84 of the ParC. Nonetheless, 690 
mutations in the gyrB and parE genes play a minor role in the acquisition of resistance 691 
to quinolones in E. coli (Vila 1994; Vila 1996; Ruiz 1997; Vila 2005; Fàbrega 2009). 692 
Another mechanism of resistance to quinolones linked to mutations in the chromosome 693 
is the reduction in the intracellular accumulation of quinolones, which may be related to 694 
a decrease in the permeability of the outer membrane or to an increased efflux of the 695 
drug out of the cell. The penetration of a quinolone through the outer membrane seems 696 
to take place in two ways, one dependent and another independent of porins. It has been 697 
suggested that the more hydrophilic quinolones, such as ciprofloxacin, cross the outer 698 
membrane only through the porins, whereas the more hydrophobic quinolones, such as 699 
nalidixic acid penetrate through the porins and non-porin pathways. Mutants of E. coli 700 
with decreased OmpF expression have a two- to four-fold decrease in susceptibility to 701 
quinolones. Several efflux pumps which affect quinolones have been described in E. 702 
coli (Vila 2011) (Table 2). However, the most important efflux pump is that encoded in 703 
the acrAB operon, in which the acrB gene encodes an inner membrane protein (AcrB), 704 
which is an efflux transporter across the inner membrane, and the acrA gene, which 705 
encodes a membrane fusion protein (AcrA). The third protein in this tripartite efflux 706 
pump is TolC which is an outer membrane protein. It has been shown that the 707 
overexpression of this efflux pump leads to a multidrug resistant phenotype in different 708 
bacteria, including E. coli (Blair 2014). A chromosomal locus, called mar (multiple 709 
antibiotic resistance), encodes a transcriptional factor which increases micF expression, 710 
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a regulatory antisense RNA, which causes a post-transcriptional decrease of OmpF 711 
RNA and reduces the amount of OmpF. In addition, MarA can also regulate the 712 
expression of AcrAB-TolC which is increased when MarA is overexpressed. This 713 
interplay between the decreased expression of OmpF and the increased expression of 714 
ArcAB-TolC generates a multidrug-resistant phenotype in E. coli with increased 715 
resistance to quinolones, chloramphenicol and tetracyclines. Besides MarA, other 716 
transcriptional activator such as SoxS has been reported in E. coli (Oethinger 1998). In 717 
addition of these global regulators MarA, SoxS and Rob in the regulation of the 718 
expression of the acrAB operon, other mechanisms of regulation have been reported in 719 
E. coli, such as: 1. Mutations in the local repressor gene acrR (Webber 2005) and 2. 720 
Insertion elements upstream of the acrAB operon, for instance in the acrR gene (Webber 721 
2001). 722 
Up to now, three plasmid-mediated mechanisms of resistance to quinolones have been 723 
described (Table 2), which are: i) the expression of an aminoglycoside-modifying 724 
enzyme (AAC(6’)Ib-cr) which has the ability to acetylate an amino group located in the 725 
piperazine ring of the quinolone structure. This enzyme affects all quinolones with the 726 
exception of those with a blocked amino group, such as levofloxacin (Cattoir 2009); ii) 727 
the qnr gene family, which encode a peptide able to protect the DNA gyrase or DNA-728 
topoisomerase IV complexes to be bound by the quinolones (Fàbrega 2009); and iii) 729 
two efflux pumps, OqxAB and QepA (Cattoir 2009). All of these genes affect relatively 730 
small increases in the MICs of quinolones, but these changes are sufficient to facilitate 731 
the selection of mutants with higher levels of resistance, mainly in the gyrA gene 732 
(Nordmann 2008). 733 
 734 
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Plasmid-Mediated AmpC-Producing Escherichia coli  735 
Plasmid-mediated AmpC (pAmpC) enzymes can be grouped into six major groups, 736 
ACC, FOX, MOX, DHA, CIT and EBC (Pérez-Pérez 2002). These enzymes are derived 737 
from the chromosomes of certain species in the Enterobacteriaceae family, but have 738 
been mobilized on plasmids that can transfer horizontally in medically important 739 
species such as E. coli, K. pneumoniae and P. mirabilis. The prevalence of these 740 
enzymes in different populations varies substantially and is also difficult to ascertain 741 
since they are not always actively searched for. 742 
Despite these limitations, some recent reports consider the prevalence of acquired 743 
AmpCs to be similar to that of extended-spectrum beta-lactamases (ESBLs) in E. coli. 744 
In the CANWARD study it was shown that ESBLs were present in 7% of E. coli 745 
isolated in 2011, whereas AmpC was detected in 3% of the cases; one third of these 746 
being sequence type 131 (ST131) (Denisiuk 2013). CMY-2 was by far the most 747 
common pAmpC found in this study (56%). In the SMART study of intraabdominal 748 
infection in the Asia Pacific region it was found that the ratio of ESBL to AmpC was 749 
7:2, and more than half of the pAmpC enzymes were CMY (Sheng 2013). The 750 
SENTRY study from the US published in 2010, comprising more than 3,000 isolates of 751 
Enterobacteriaceae showed that 0.5% of the isolates had pAmpC, and also in this case 752 
CMY-2 was also the most commonly detected. Finally, a recent Swedish investigation 753 
of a national collection of E. coli with resistance to extended-spectrum cephalosporins 754 
(n=409) showed that 7% of the isolates had pAmpC enzymes of the CMY-type, 755 
whereas the remaining 93% were ESBL-producing (Brolund 2014). 756 
CMY-2 is by far the most commonly reported pAmpC-variant and is frequently 757 
associated with IncA/C broad range plasmids. Such plasmids have been isolated from 758 
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both from humans and animals, and in both in E. coli and Salmonella spp (Carattoli 759 
2012). The second most common replicon type associated with CMY-2 is I1, whereas 760 
other replicon types have been reported sporadically (Carattoli 2009). Compared to 761 
other pAmpC variants the success of CMY-2 is probably associated with its relationship 762 
with insertion sequence ISEcp1 (Naseer 2010) which provides the promotor regions that 763 
drives high-level expression of blaCMY (Nakano 2007), similar to what has been 764 
observed for blaCTX-M-15, a highly successful ESBL. 765 
It is of note that pAmpCs are now been frequently observed both in food-producing and 766 
companion animals. Recent data from The Netherlands have shown a high occurrence 767 
in the broiler production (Dierikx 2013). This finding was corroborated by recent 768 
Swedish data showing frequent occurrence of pAmpCs in Swedish broilers, which 769 
could be explained by vertical transmission in the production pyramid through imported 770 
grandparent poultry (Nilsson 2014). However, Swedish data do not support 771 
transmission between animals and humans (Börjesson 2013). The presence of pAmpC 772 
has also been seen in both healthy and diarrheic dogs and cats (Hordijk 2013). 773 
It has only been recently that EUCAST published the first international guidelines for 774 
the detection of pAmpC (Leclercq 2013). It has been shown that pAmpCs are more 775 
often associated with a multidrug-resistant phenotype than isolates with chromosomal 776 
hyper-production of AmpC, but in some areas, isolates producing pAmpC can be 777 
relatively susceptible to other drug classes (Edquist 2013). Phenotypic methods for the 778 
detection of pAmpC have relatively high sensitivities but cannot differentiate between 779 
AmpC of chromosomal- or plasmidic-origin. For this purpose, several molecular 780 
methods have been described including both in-house and commercial assays (Bogaerts 781 
2011).   782 
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CMY-2 has all the hallmarks of a successful enzyme, including a link to ISEcp1, broad-783 
range plasmids, and to ST131. Monitoring the occurrence of pAmpC in E. coli could 784 
therefore be warranted for infection control purposes and surveillance, at least in highly 785 
clinically-important sample types like blood cultures. 786 
 787 
Carbapenemase-Producing Escherichia coli   788 
The safety, reliable killing properties and clinical efficacy of β-lactams place these 789 
antibiotics among those most frequently prescribed for the treatment of bacterial 790 
infections. Among them, carbapenems have the broadest spectrum of activity and are 791 
the drugs of choice to treat serious infections caused by extended-spectrum ß-lactamase 792 
(ESBL)-producing Enterobacteriaceae. However, their utility is being threatened by the 793 
proliferation of carbapenem-resistant Enterobacteriaceae (CRE) worldwide. Several 794 
mechanisms of carbapenem resistance have been reported: (i) the presence of ESBLs or 795 
AmpC enzymes in combination with porin mutations, and (ii) the production of 796 
carbapenemases (Cuzon 2010a; Nordmann 2011). Clinically-relevant carbapenemases 797 
encountered in E. coli belong to Ambler class A enzymes, such as KPC and GES, to 798 
class D enzymes, such as OXA-48, or to metallo-ß-lactamases (MBLs) such as IMP, 799 
VIM or NDM (Nordmann 2011). The dissemination of these enzymes among E. coli is 800 
a matter of great clinical concern given the major role of this pathogen as a cause of 801 
nosocomial as well as community-acquired infections (Tzouvelekis 2014; Glasner 802 
2013). Carbapenemase-producing (CP) E. coli isolates are often resistant to most classes 803 
of antibiotics, leaving physicians with very limited antibiotic choices, if any, for treating 804 
infected patients (Tzouvelekis 2014; Falagas 2014). In general, infections due to CP-E. 805 
coli isolates were previously limited to frail and debilitated people in hospital settings. 806 
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However, CP-E. coli isolates are now spreading in the community and represent a rising 807 
threat to the general population (Nordmann 2011; Cantón 2012; Falagas 2014).  808 
In early 2012, carbapenem-resistant K. pneumoniae were already endemic in countries 809 
such as India, Morocco, USA, Israel and Greece, and their presence had started to rise 810 
in many European countries (Nordmann 2011; Cantón 2012). This drastic increase is 811 
best exemplified by the Italian situation, in which the prevalence of carbapenem 812 
resistance among K. pneumoniae isolated from blood cultures rose from 1 % in 2009 to 813 
30 % in 2012 (www.ecdc.europa.eu). In countries with a high prevalence of CP- K. 814 
pneumoniae isolates, significant increases have recently been witnessed in the 815 
prevalence of CP-E. coli in Greece, Italy, the Czech Republic, Slovakia, Hungary, 816 
Bulgaria, with a prevalence of 1.6%, 0.3%, 0.7 %, 1.3 %, 0.1 %, 2.6 % respectively 817 
(www.ecdc.europa.eu). CP-E. coli isolates are now increasingly reported in many 818 
countries worldwide (Nordmann 2011; Cantón 2012). France has been previously a 819 
country with low prevalence of CP-Enterobacteriaceae (www.invs.sante.fr; Dortet 820 
2014); however, the number of episodes per year significantly rose from 1 to 415 821 
episodes/year from 2008 to 2013 (one episode being either a single case or an outbreak 822 
of CP-Enterobactericeae), and E. coli now represents 30% of these episodes 823 
(www.invs.sante.fr; Dortet 2014). While 2/3 of the cases were colonisations, life-824 
threatening bacteraemia has also been described in association with high mortality rates 825 
(www.invs.sante.fr). 826 
CP-E. coli isolates have now been isolated worldwide; however, the distribution of the 827 
different carbapenemases varies from continent to continent and even from country to 828 
country (Nordmann 2011; Cantón 2012). KPC enzymes are more prevalent in the 829 
Americas, Greece, Italy, Israel, and China (Nordmann 2009; Cantón 2012; Glasner 830 
2013). MBLs of the IMP-type seem mainly restricted to the Asian continent (especially 831 
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Japan) and are only rarely identified in Europe among enterobacterial isolates 832 
(Nordmann 2009; Cantón 2012; www.invs.sante.fr). MBLs of the VIM-type have been 833 
identified worldwide in enterobacterial isolates responsible for large hospital outbreaks. 834 
In Europe, Greece has observed a massive spread in these isolates, and major outbreaks 835 
have been reported in Spain (Cantón 2012; Kazmierczak 2015). The latest MBL 836 
described, NDM-1 (New Delhi Metallo-ß-lactamase), is highly prevalent in the Indian 837 
sub-continent but has also now been identified in many countries worldwide underlining 838 
its rapid diffusion (Nordmann 2011; Cantón 2012; Walsh 2011). OXA-48 producers are 839 
spreading in many countries in Europe, in the southern and eastern part of the 840 
Mediterranean Sea, North Africa, and India, but identification on all continents have 841 
been reported (Poirel 2012a). In France, OXA-48 is the most prevalent carbapenemase 842 
and is isolated in 85% of the CP-E. coli isolates, suggesting a likely community spread 843 
(www.invs.sante.fr; Dortet 2014).  844 
The emergence and rapid spread of these carbapenemases is, in part, the consequence of 845 
mobile genetic elements (Tn4401 for KPC-2, Tn1999 for OXA-48, Tn125 for NDM-1 846 
and Tn21 associated with integrons for VIM/IMP) as well as the existence of highly 847 
efficient conjugative plasmids (pOXA-48 of IncL/M-type) and epidemic clones at the 848 
origin of their diffusion worldwide (K. pneumoniae ST258 for KPC) (Aubert 2006; 849 
Naas 2008; Cuzon 2010b; Poirel 2012b; Potron 2014; Mathers 2015a; Zhao 2015). 850 
MLST analysis of a worldwide collection of OXA-48 producing E. coli isolates has 851 
revealed a high degree of diversity among the isolates, suggesting the spread of a single 852 
epidemic plasmid pOXA-48 in different clones (Potron 2013). However, 853 
carbapenemases such as OXA-48, NDM-1, KPC-2 or VIM-2 have also now been 854 
reported in successful epidemic E. coli clones; for example in the widespread E. coli 855 
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ST131 responsible for the spread of the CTX-M-15 ESBL (Naas 2011; Woodford 2011; 856 
Bonnin 2012; Morris 2012). 857 
As underscored in the last WHO global report (WHO 2014), antimicrobial resistance 858 
within a wide range of infectious agents including E. coli has reached an extremely 859 
worrying situation, that “threatens the achievements of modern medicine” (WHO 2014). 860 
While it is difficult to anticipate the development of novel antimicrobial agents, most 861 
efforts must be focused on the prevention of the spread of carbapenemase producers by 862 
early detection and reinforced hygiene measures (Delory 2015). Detection of CP-E. coli 863 
isolates is often difficult due to low carbapenem MICs that may remain within the 864 
susceptibility range. Reduced susceptibility to carbapenems should alert microbiologists 865 
to perform confirmatory testing. The last years have witnessed the development of 866 
several efficient confirmatory tests (biochemical-, spectrometric-, and molecular-tests) 867 
(Dortet 2015; Viau 2016). In hospital settings, screened patients are kept in strict 868 
isolation until screening results are available, thereby requiring screening techniques to 869 
be sensitive, specific, and rapid. Since the reservoir of carbapenemase producers 870 
continues to be the intestinal flora, stools and rectal swabs are adequate samples for 871 
performing this screening. Several selective chromogenic media and molecular tests are 872 
now available to improve the screening of carriers (Viau 2016). 873 
 874 
Genetic Elements Carrying Resistance Determinants  875 
The dissemination of antimicrobial resistance in E. coli has been largely attributed to 876 
inter- and intra-specific DNA exchange, with horizontal transfer of plasmid-located 877 
genes being the prevalent mechanism at the origin of the acquisition of resistance. 878 
Plasmids are members of the prokaryotic family of mobile genetic elements, which play 879 
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a central role in mobilizing and reorganizing genes within the genome (intracellular 880 
mobility) or between different bacterial cells (intercellular mobility) (Thomas 2005). 881 
Plasmids promote the horizontal transfer of resistance determinants among bacteria of 882 
different species, genera and kingdoms, depending on their narrow or broad host range, 883 
conjugative properties and efficiency of conjugation (Lawley 2004). Natural plasmids 884 
have systems guaranteeing their autonomous replication as well as mechanisms 885 
controlling the copy-number and ensuring stable inheritance during cell division 886 
(Sykora 1992; Thomas 2005). Plasmids acquire mobile genetic elements (insertion 887 
sequences, transposons) that mobilize the antimicrobial resistance genes. In many 888 
plasmids, mobile genetic determinants are integrated in clusters, conferring resistance to 889 
multiple classes of antibiotics. These plasmids may grant a selective advantage to the 890 
bacterial host when several antimicrobials are simultaneously administered (Miriagou 891 
2006).  892 
Particular plasmid types are more frequently detected in E. coli and play a major role in 893 
the diffusion of specific resistance genes. For instance, IncFII, IncN and IncI1 plasmids 894 
carrying extended-spectrum beta-lactamase genes are currently considered as “epidemic 895 
resistance plasmids” in this species, being detected worldwide in E. coli of different 896 
origins and sources (Carattoli 2013).  897 
The IncI1 resistance plasmids are one of the most diffused plasmid families in E. coli, 898 
and they largely contributed to the dissemination of ESBLs, in particular of the CTX-M 899 
type (Carattoli 2013). IncI1 plasmids are characterized by the presence of a cluster 900 
encoding the type IV pili, contributing to adhesion and invasion of Shiga-toxigenic E. 901 
coli (STEC) (Kim 1997). These peculiar pili are considered a virulence factor which, in 902 
association with resistance determinants, may support their successful dissemination. 903 
More than 400 IncI1 plasmids are currently included in the database of plasmid 904 
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MultiLocus Sequence Typing (pMLST). This method allows the classification of the 905 
plasmids of the most frequent families in homology groups named Sequence Types 906 
(STs; http://pubmlst.org/plasmid/). Interestingly, IncI1 plasmids assigned to ST7 907 
represent 56% (75/136) of all the blaCTX-M-1 carrying plasmids from E. coli submitted to 908 
the pMLST database, suggesting that the spread of the CTX-M-1 ESBL is mainly due to 909 
one single plasmid circulating in different E. coli strains. This variant has been 910 
identified in E. coli strains from poultry meat samples and human sources in different 911 
European countries, demonstrating that these plasmids are capable of spreading very 912 
efficiently and might have a reservoir in the food chain (Leverstein-van Hall 2011).  913 
The blaCTX-M-1 was also identified on plasmids belonging to the IncN group in human 914 
clinical strains of E. coli in pigs and farm personnel from Denmark, and it was 915 
demonstrated that these plasmids were transmitted within the farm among pigs and the 916 
farm workers, across multiple E. coli lineages (Moodley 2009). In Greece and Italy, 917 
IncN plasmids originated the dissemination of the metallo beta-lactamase VIM-1. These 918 
plasmids have frequently been identified in K. pneumoniae as well as E. coli of 919 
nosocomial origin, persisting for a long time in different hospitals, and also acquiring 920 
Plasmid Mediated Quinolone Resistance (PMQR) genes and other additional resistance 921 
determinants. These plasmids encode the EcoRII endonucleases/methylase restriction 922 
system and demonstrate the integration of a variable region consisting of multiple 923 
integrons and transposons within the fipA target site, a dispensable plasmid gene that 924 
probably creates a region prone to acquiring transposon- and insertion sequences 925 
(Miriagou 2010; Carattoli 2010). 926 
Since 2000, CTX-M-15 has become the most common CTX-M variant, having been 927 
mainly identified in the pandemic, multi-resistant, virulent E. coli O25:H4-ST131 clone 928 
(Cantón 2006). The blaCTX-M-15 gene has been associated with multireplicon plasmids 929 
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belonging to the IncF group. An interesting study performed in Enterobacteriaceae, not 930 
pre-selected for antimicrobial resistance demonstrated that IncF plasmids are unevenly 931 
distributed between the different species, being more prevalent in E. coli than in other 932 
genera (Sherley 2003). These data suggest that the bla CTX-M-15 gene has been acquired 933 
on a plasmid type that frequently occurs in the E. coli species. In many E. coli strains 934 
the bla CTX-M-15 gene has been associated with additional resistance genes on the same 935 
IncF plasmid such as the blaOXA-1 and blaTEM-1 beta-lactamases, the aac(6’)-Ib-cr and 936 
aac(3)-II aminoglycoside- and fluoroquinolone-resistance genes, the tetracycline 937 
resistance operon, conferring altogether a multi-drug resistance phenotype to these 938 
strains (Karisik 2006; Woodford 2009). IncF plasmids likely contribute not only to the 939 
fitness of the bacterial host by providing virulence and antimicrobial resistance 940 
determinants but also encoding several addiction systems that guarantee their 941 
maintenance and stability in the host cell independently by the positive selective 942 
pressure exerted by the antimicrobials.  943 
The blaNDM-1 gene is mostly plasmid-located and several different plasmid types, 944 
including IncL/M, IncA/C, IncF, IncHI1 and novel plasmid variants of the IncN and 945 
IncHI1 type were at the origin of the dissemination of the blaNDM-1 gene in non-946 
clonally-related enterobacterial isolates. IncA/C plasmids are particularly important 947 
since they show a very broad host range, being able to replicate not only in 948 
Enterobacteriaceae, but also in Pseudomonas (Carattoli 2012). Plasmids of this group 949 
carry multiple resistance determinants, conferring aminoglycoside, chloramphenicol, 950 
trimethoprim, sulphonamides, tetracycline, and the mercuric ion and encode restriction 951 
enzymes, antirestriction DNA methylases, and partitioning systems that promote their 952 
maintenance and persistence. In the last decades, IncA/C plasmids have been associated 953 
with the spread of the AmpC beta lactamase CMY-2 in E. coli (Lindsey 2009). The 954 
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NDM-1-IncA/C plasmids derive from those carrying the blaCMY-2 gene, since a 955 
conserved genetic environment of the bla CMY-2 gene and the same integration site 956 
within the plasmid have been observed. It is plausible that the IncA/C plasmids evolved 957 
by sequential acquisition of the bla CMY-2 gene, followed by the acquisition of the 958 
blaNDM-1 gene and also gained further additional resistance determinants encoding the 959 
ArmA or RmtB 16S RNA methylases, conferring resistance to all aminoglycosides 960 
(Carattoli 2012) (Figure 5). 961 
 962 
CLINICAL ASPECTS OF Escherichia coli 963 
Escherichia coli and Inflammatory Bowel Diseases 964 
Inflammatory bowel disease (IBD) comprises a group of chronic remitting-relapsing 965 
inflammatory bowel disorders of unknown etiology that predominantly affect 966 
industrialized countries. Crohn’s disease (CD) and ulcerative colitis (UC) are the main 967 
IBDs and, although they share similar clinical symptoms, they are histopathologically 968 
distinct and are suspected to have different etiologies (Sartor 2006). The intestinal 969 
microbiota is one of the main factors implicated in IBD, however it is still unclear 970 
which specific bacterial communities are responsible for the unbalanced host-microbe 971 
relationships in these diseases. A large number of studies agree that dysbiosis in CD is 972 
characterized by an increase in E. coli and a decrease in Faecalibacterium prausnitzii 973 
(Martinez-Medina 2006; Willing 2009; Lopez-Siles 2014), whereas no such consensus 974 
has been reached for dysbiosis in UC patients (Martinez-Medina 2014a). Regarding the 975 
role of E. coli, substantial evidence indicates that E. coli is involved in CD, especially 976 
ileal CD, and growing data suggest that this species is also a contributing factor in the 977 
pathogenesis of UC.   978 
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E. coli is a natural colonizer of the human intestinal tract and some pathogenic strains, 979 
classified into six pathovars and collectively named diarrhoeagenic E. coli, can lead to 980 
intestinal disease (Kaper 2004). However, diarrhoeagenic E. coli has rarely been 981 
detected in IBD patients (Baumgart 2007). Instead, strains with features characteristic of 982 
ExPEC have frequently been associated with the intestinal mucosa of these patients 983 
(Baumgart 2007; Schippa 2009; Vejborg 2011). It is of note that ExPEC-like strains 984 
with virulence genes such as adhesins, siderophores, capsule or toxins are also common 985 
in the mucosa of healthy subjects and are reportedly necessary for an effective 986 
colonization of the intestinal tract (Nowrouzian 2001). Despite the common features 987 
between E. coli populations from IBD and healthy subjects, differences in terms of 988 
abundance and pathogenic behavior have been described. 989 
In patients with CD, especially those with ileal and active disease, there is an 990 
overgrowth of E. coli (Baumgart 2007; Willing 2009; Schwiertz 2010; Lopez-Siles 991 
2014), and increased abundance of this species has been correlated with lower time until 992 
relapse (Lopez-Siles 2014). E. coli can be frequently found in the mucosa inside 993 
intestinal epithelial cells and translocated in the lamina propia or deeper in the mucosa 994 
and submucosa, as well as in germinal centers of lymph follicles and within granulomas 995 
(Mylonaki 2005). Molecular characterization of isolated strains has demonstrated that E. 996 
coli from CD patients are ExPEC-like and mainly belong to B2 and D phylogroups 997 
(Baumgart 2007; Schippa 2009), but studies conducted by Darfeuille-Michaud and 998 
collaborators revealed that many of CD isolates shared phenotypic pathogenic features 999 
that were not consistent with their genetic basis. Thus, a new E. coli pathotype 1000 
associated with CD named Adherent-Invasive E. coli (AIEC) was defined (Darfeuille-1001 
Michaud 2004). 1002 
Page 43 of 107
ScholarOne Support 1-434/964-4100
FEMS Microbiology Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
43 
 
In patients with UC, there is some controversy regarding the abundance of E. coli, its 1003 
localisation in the mucosa and the pathogenic features of the strains, and thus, further 1004 
research is needed to clarify these aspects (Martinez-Medina 2014a). However, recent 1005 
studies support that E. coli abundance is increased in patients with active disease 1006 
(Pilarczyk-Zurek 2013), and some reports indicate that E. coli can be found inside 1007 
intestinal epithelial cells and in the lamina propia of UC patients (Myonaki 2005). As 1008 
for CD, E. coli isolated to date are mainly ExPEC-like and belong to the B2 and D 1009 
phylogroups (Schippa 2009). However, recent studies have shown that genes encoding 1010 
for hemolysin, cytotoxic necrotizing factor 1, polyketide synthase gene complex (pks) 1011 
and other virulence factors are more frequent in UC than in CD E. coli (Curova 2009; 1012 
Pilarczyk-Zurek 2013). Altogether, this suggests that specific E. coli subtypes with 1013 
cytotoxic and genotoxic properties may be the responsible for, or contribute to the 1014 
mucosal inflammation and tissue damage in patients with UC. 1015 
The Adherent-Invasive E. coli (AIEC) pathotype was defined based on phenotypic traits 1016 
as strains that adhere to and invade intestinal epithelial cells involving host cell actin 1017 
polymerization and microtubule recruitment, and with the ability to survive and 1018 
replicate within macrophages without inducing host cell death (Darfeuille-Michaud 1019 
2004).  1020 
In the last decade, several independent studies have reported a higher prevalence of 1021 
AIEC in CD, ranging from 25 to 66% in CD patients and from 0% to 18% in healthy 1022 
subjects (Baumgart 2007; Dogan 2013). Moreover, an increased abundance and richness 1023 
was especially evident for patients with ileal CD. Few studies have sought to investigate 1024 
the presence of AIEC in UC and prevalence reported to date ranges from 0% to 37.5% 1025 
(Darfeuille-Michaud 2004; Curova 2009; Negroni 2012). However, the whole AIEC 1026 
phenotype was not analyzed in all the studies. Further studies are needed to confirm the 1027 
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disease specificity of AIEC, not only focused on UC but also on colorectal cancer or 1028 
coeliac disease, since particular subsets of E. coli with ExPEC features have also been 1029 
detected in these disorders (Sanchez 2008). Concerning host specificity, two studies 1030 
demonstrate that the AIEC pathotype may also play a role in intestinal disease in dogs, 1031 
cats and swine, suggesting a certain risk of zoonosis (Martinez-Medina 2011). 1032 
Moreover, recent studies have suggested that high fat – high sugar diets as well as food 1033 
emulsifiers and stabilizers often found in the food of industrialized countries can favor 1034 
AIEC gut colonization (Martinez-Medina 2014b). 1035 
The molecular mechanisms of pathogenicity have principally been studied in one AIEC 1036 
reference strain, named LF82. Adhesion to intestinal epithelial cells is mainly mediated 1037 
by the interaction between FimH adhesin of type 1 fimbriae and host CEACAM6 1038 
glycoprotein, which is overexpressed in CD (Barnich 2007). Moreover, mutations of a 1039 
recent evolutionary origin that confer a higher ability to adhere to CEACAM6 have 1040 
frequently been found in AIEC FimH (Dreux 2013). Reduced amounts of the bacterial 1041 
second messenger c-di-GMP stimulate the expression of flagella and type 1 pili in strain 1042 
LF82, promoting adhesion and invasion (Claret 2007; see biofilm specific section for 1043 
more information about c-di-GMP). Genomic analyses have shown mutations in some 1044 
phosphodiesterases and diguanylate cyclases that may affect c-di-GMP levels in three 1045 
AIEC strains (Povolotsky 2015). Decreased concentration of c-di-GMP is associated 1046 
with motile phenotypes whereas high cellular levels promote biofilm formation. 1047 
Nonetheless, biofilm formation is a feature of not only the LF82 strain (Chassaing 1048 
2013) but also of a substantial number of AIEC strains (Martinez-Medina 2009b,c). 1049 
Further studies focused on the implications of c-di-GMP turnover in AIEC pathogenesis 1050 
and in the whole gut microbiota are of interest, especially because the 1051 
immunosuppressive drug azathioprine used in inflammatory bowel disease inhibits the 1052 
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biosynthesis of c-di-GMP (Antoniani 2015). Apart from type 1 pili mediated adhesion, 1053 
an interaction between chitinases of bacterial and human origin has been elucidated 1054 
(Low 2013). Particularly, specific polymorphisms in two chiA chitin binding domains 1055 
characteristic of LF82 and other pathogenic E. coli are required to interact with human 1056 
chitinase CHI3L1, which is up-regulated during intestinal inflammation. Invasion of 1057 
intestinal epithelial cells by LF82 is in part mediated by outer membrane vesicles that 1058 
interact with host receptor Gp96 via the OmpA. These vesicles are thought to contain 1059 
bacterial effectors that are released into the host cell and can induce the actin 1060 
polymerization and microtubule recruitment occurring during bacterial uptake (Rolhion 1061 
2010). Intracellular replication is possible since LF82 is able to abrogate autophagy by 1062 
inducing the overexpression of MIR30C and MIR130A, which, in turn, reduce the 1063 
expression of ATG5 and ATG16L1 autophagy-related molecules (Nguyen 2013). 1064 
However, polymorphisms in genes related to autophagy have been associated with CD, 1065 
therefore host susceptibility may influence the success of AIEC to survive inside human 1066 
cells as well (Lapaquette 2010). LF82 can also easily translocate the intestinal barrier 1067 
via M cells by the interaction of type 1 pili and long polar fimbriae with the GP2 M cell 1068 
receptor (Chassaing 2011) and also intercellularly since LF82 can lead to a loss of gut 1069 
barrier function by inducing the expression of the pore-forming protein claudin-2 and 1070 
by displacing ZO-1 and E-cadherin from apical tight junctions (Denizot 2012). In 1071 
macrophages, intracellular AIEC replicate within the phagolysosome, thus indicating 1072 
that they have the ability to resist and replicate in acidic environments, under oxidative 1073 
stress and in the presence of antimicrobial peptides (Bringer 2006). It has been 1074 
demonstrated that the protease HtrA, the thiol-disulfide oxidoreductase DsbA (Bringer 1075 
2007) and unknown target genes of the RNA-binding protein Hfq play a role in LF82 1076 
intramacrophagic survival (Simonsen 2011). In turn, infected macrophages secrete high 1077 
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amounts of TNFα, which contributes to intestinal inflammation and CEACAM6 1078 
expression, thus facilitating AIEC adhesion to intestinal epithelial cells. A direct role for 1079 
LF82 in delaying apoptosis of macrophages and dendritic cells has recently been 1080 
reported (Dunne 2013). Interestingly, this trait can be linked to granuloma formation, a 1081 
hallmark in the pathogenesis of CD. Survival and replication within neutrophils has also 1082 
been reported for LF82, but in this cell line type LF82 induces apoptosis (Chargui 1083 
2012). Infected neutrophils secrete IL-8 also contributing to mucosal inflammation. 1084 
Despite all these mechanisms of pathogenicity, AIEC are considered pathobionts rather 1085 
than true pathogens. This notion is supported by the fact that AIEC is also found in the 1086 
intestinal mucosa of healthy subjects, albeit with a lower abundance than in CD, and 1087 
that host genetic susceptibility and/or environmental risk factors may have an impact on 1088 
the success of AIEC to colonize the gut and cause disease. As evidenced in animal 1089 
models, an alteration of the endogenous microbiota or the induction of a low-grade 1090 
inflammation is necessary for effective colonization of AIEC (Carvalho 2009). 1091 
In summary, gut bacterial dysbiosis in IBD has led to the study of E. coli 1092 
populations in CD and UC, which is still an active area of research with many 1093 
unresolved questions. Distinct E. coli pathosubtypes have been suggested to be 1094 
implicated in the pathogenesis of CD and UC. CD associated E. coli are frequently 1095 
classified as AIEC and recently, E. coli with toxigenic features have been associated 1096 
with UC. Significant efforts have been dedicated to defining the molecular mechanisms 1097 
of the pathogenicity of the AIEC pathotype. However, these studies have mainly been 1098 
focused on the LF82 strain and no specific genes for the pathotype have been identified 1099 
to date. Genomic and transcriptomic analyses of a wider AIEC collection including 1100 
different phylotypes will facilitate the identification of biological markers for the 1101 
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molecular identification of the pathotype as well as to shed light on the molecular basis 1102 
of its pathogenicity. 1103 
 1104 
Urinary Tract Infection Caused by Escherichia coli 1105 
E. coli is the principal cause of UTI which can present as asymptomatic bacteriuria, 1106 
cystitis, and pyelonephritis, as well as prostatitis in men. Uropathogenic E. coli (UPEC) 1107 
is the etiological agent in 75 % of uncomplicated UTI and 65 % of complicated UTI 1108 
(Flores-Mireles 2015). 1109 
UPEC have diverse virulence factors (Lüthje 2014; Subashchandrabose 2015), some of 1110 
them related to pathogenicity islands, regions of DNA that are acquired by horizontal 1111 
gene transfer. These virulence factors are: 1112 
1. Adhesins: fimbriae or pili as type 1 fimbriae, P fimbriae (related with renal 1113 
cells adherence), curli fimbriae, F1c/s fimbriae, F9 and type 3 fimbriae; and 1114 
non-fimbrial adhesins (Afa/Dr adhesins, related with diarrheagic diseases) 1115 
and autotransporter proteins (Ag43 adhesin and Upa uropathogenic 1116 
autotransporter protein). These adhesins are responsible for adhesion to both 1117 
urinary tract epithelial cells and urinary catheters, and promote biofilm 1118 
formation. 1119 
2. Toxins: endotoxin lipopolysaccharide (LPS), α-haemolysin (HlyA), CNF1 1120 
(cytotoxic necrotizing factor 1) and SPATEs (serine protease 1121 
autotransporters of the Enterobacteriaceae) as Sat (Secreted Autotransported 1122 
Toxin), Pic (Protease Involved in Colonization) or Vat (Vacuolating 1123 
Autotrasported Protein). These toxins are related to dissemination in tissues, 1124 
inflammatory response, cytotoxicity and resistance to neutrophils. 1125 
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3. Iron acquisition mechanisms: Haem receptors (iron Haem uptake regulated 1126 
by ChuA and Hma) and siderophores (iron chelating molecules as 1127 
enterobactin, aerobactin, salmochelin and yersiniabactin). Both mechanisms 1128 
promote the availability of iron in the urinary tract and contribute to survival 1129 
and persistence in the urinary tract. Zinc acquisition mechanisms are also 1130 
important. 1131 
4. Immune evasion mechanisms: suppression of induction of cytokines and 1132 
chemokines (due to O antigens of LPS), serum resistance and protection 1133 
against phagocytes (due to O antigens of LPS and K antigens of capsular 1134 
polysaccharides) and motility (due to flagella with F antigens). 1135 
5. Formation of biofilm: extracellular matrix that provides protection against 1136 
antimicrobial treatment and host defense mechanisms and adherence to both 1137 
epithelial cells and urinary catheters, and is responsible of persistence and 1138 
recurrence of UTI. 1139 
E. coli may be classified in phylogroups A, B1, B2, D and E; UPEC belong usually to 1140 
phylogroup B2 and less frequently to phylogroup D. Classification is also possible by O 1141 
(somatic), H (flagellar) or K (capsular) antigens (Lüthje 2014; Dale 2015). Commonly 1142 
used molecular classification systems include multilocus sequence typing (MLST), 1143 
pulsed field gel electrophoresis (PFGE) and, recently, whole genome sequencing 1144 
(WGS) (Dale 2015). 1145 
Treatment of uncomplicated cystitis include nitrofurantoin, trimethoprim-1146 
sulfametoxazol, fosfomycin or, less frequently, oral fluoroquinolones or β-lactam 1147 
antibiotics such as amoxicillin-clavulanate or 2nd or 3rd generation cephalosporins. In 1148 
pyelonephritis, recommended treatment includes intravenous ceftriaxone, 1149 
aminoglycoside, fluoroquinolones or carbapenems (Gupta 2011). 1150 
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In Europe (European Centre for Disease Prevention and Control 2014) the prevalence in 1151 
E. coli of resistance to aminopenicillins (ampicillin or amoxicillin) is 57.1 %, to 1152 
fluoroquinolones is 22.4 %, to 3rd generation cephalosporins is 12,0 % (due to the 1153 
production of ESBLs) and to aminoglycosides (gentamycin or tobramycin) is 9,8 %. 1154 
Moreover, 4.8 % of strains are co-resistant to 3rd generation cephalosporines, 1155 
fluoroquinolones and aminoglycosides, thereby demonstrating multidrug resistance. 1156 
Only 0.1 % of E. coli are resistant to carbapenems, and only 7.8 % of gentamicin and/or 1157 
tobramycin-resistant strains are amikacin-resistant. These data suggest that 1158 
recommended empiric treatment of UTI may be adapted to the changing antimicrobial 1159 
susceptibility. 1160 
E. coli sequence type 131 (ST131) is a clonal group that has spread in diverse countries 1161 
in recent years (Banerjee 2014; Mathers 2015b). This clone belongs to phylogenetic 1162 
group B2 and is composed by different subclones: the original H30 subclone susceptible 1163 
to antibiotics has evolved to the H30R subclone, resistant to fluoroquinolones (with 1164 
mutant gyrA and parC alleles), and these to the H30Rx subclone, resistant also to 3rd 1165 
generation cephalosporins (due to ESBL CTX-M-15). The most important clusters are 1166 
O25b:H4 (dominated by H30 strains) and, less frequently, O16:H5. E. coli O16:H5 is 1167 
more resistant to gentamycin and trimethoprim-sulfametoxazol, but less resistant to 1168 
fluoroquinolones and 3rd generation cephalosporins than E. coli O25b:H4. 1169 
E. coli ST-131 is a problem from public health due to its global distribution, increased 1170 
transmissibility, ability to colonize and persist in intestine and urinary tract, enhanced 1171 
virulence (great number of virulence genes and high fitness), and extensive antibiotic 1172 
resistance. This clone has been described more frequently in patients older than 50 1173 
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years, in previous antibiotics consumption, health-care associated UTI and recurrent and 1174 
persistent UTI and sepsis. 1175 
Prevention of recurrent and/or persist UTI, which is especially frequent in women, is an 1176 
important question to resolve. The use of Lactobacillus, both in oral formulation or in 1177 
vaginally inserted capsules, is controverted. Lactobacillus maintains acid vaginal pH 1178 
(less than 4.5), produces H2O2 and bacteriocins for bacterial lysis and biosurfactants that 1179 
reduce adhesion, and can co-agglutinate with uropathogens. Despite these 1180 
characteristics, the utility of Lactobacillus for preventing UTI has not been proven 1181 
(Barrons 2008). 1182 
The use of cranberries for prevention of recurrent and/or persist UTI had also 1183 
interesting. Cranberries (Vaccinium macrocarpon) contain proanthocyanidins (PACs) 1184 
with antiadhesion activity (Howell 2007), specifically against P fimbriae, reducing 1185 
fimbrial length and density, and producing morphological changes. But the most recent 1186 
studies of the use of cranberry juice, concentrate, capsules or tablets have not 1187 
demonstrated utility in reducing occurrence of UTI (Jepson 2012). 1188 
The final promising approach for preventing these infections is the use different kinds 1189 
of vaccines and small molecules that are directed toward virulence factors. Candidate 1190 
vaccines include those that target bacterial adhesins (e.g., PapD-PapG or FimC-FimH 1191 
chaperone adhesion complexes), toxins (e.g., haemolysin HlyA) and proteases, or 1192 
siderophores (e.g., FyuA, Hma, IutA and IrcA). Small molecules can target bacterial 1193 
adhesion by inhibiting pili function (e.g., mannosides) or assembly (e.g., pilicides) 1194 
(Flores-Mireles 2015) 1195 
 1196 
Treatment of Infections Caused by Multidrug-Resistant Escherichia coli 1197 
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E. coli is the most frequent cause of community and healthcare-associated UTIs, and is 1198 
frequently involved in intraabdominal infections. Therefore, antimicrobial resistance in 1199 
E. coli has an important impact on the empirical regimens appropriate for these 1200 
syndromes and, consequently, on the use of specific antimicrobial agents.  1201 
There are plentiful of options for the treatment of severe infections caused by 1202 
susceptible E. coli, including penicillins, β-lactam/ β-lactamase inhibitor combinations 1203 
(BLBLI), cephalosporins, monobactams, carbapenems, fluoroquinolones, 1204 
aminoglycosides, and trimethoprim-sulfamethoxazole (TMP-SMX), among others. 1205 
However, the spread of antimicrobial resistance in E. coli due to specific successful 1206 
clones or transmissible resistance mechanisms significantly limits the options in real 1207 
life. In fact, according to the ECDC definitions (Magiorakos 2012), multidrug-1208 
resistance is frequent in E. coli. During the last decades, fluoroquinolone resistance and 1209 
the production of extended-spectrum β-lactamase (ESBL) or plasmid-mediated AmpC 1210 
(pAmpC) have increased dramatically worldwide, albeit with important regional 1211 
variations.  1212 
 1213 
Therapy of ESBL- and pAmpC- producers. These isolates are usually resistant to 1214 
penicillins, fluoroquinolones, TMP-SMX, and some aminoglycosides. Carbapenems are 1215 
usually considered the drug of choice for the treatment of severe infections caused by 1216 
isolates producing ESBLs (Rodríguez-Baño 2008) because their activity is unaffected 1217 
by these enzymes. In addition, the results of some observational studies have suggested 1218 
that carbapenems are associated with better outcomes than cephalosporins or 1219 
fluoroquinolones (Vardakas 2012). The same is assumed for pAmpC-producers despite 1220 
the scarcity of data. There is greater experience with imipenem and meropenem, and 1221 
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more recently with ertapenem (Wu 2012), which may have the advantage of not 1222 
providing selective pressure on Pseudomonas aeruginosa (Nicolau 2012). The presence 1223 
of these enzymes in community isolates has led to an increase in the consumption of 1224 
carbapenems (Laxminarayan 2013), which is worrisome in the present context of 1225 
emergence of carbapenemase-producers. Therefore, the search for alternatives to 1226 
carbapenems for ESBL-producers is necessary. 1227 
ESBL (but not AmpC) are inhibited by β-lactamase inhibitors, and thus BLBLI such as 1228 
amoxicillin-clavulanic acid or piperacillin-tazobactam are active against some ESBL-1229 
producers, again with regional variations. Whether BLBLI are as effective as 1230 
carbapenems is controversial. Piperacillin-tazobactam but not amoxicillin-clavulanic 1231 
acid has shown reduced activity when tested against high inoculum of E. coli 1232 
(producing or not producing ESBLs) both in vitro (Docobo-Pérez 2013) and in vivo 1233 
(López-Cerero 2010). However, the results of a recent post-hoc analysis of several 1234 
prospective cohorts of patients with bloodstream infections (BSI) due to ESBL-1235 
producing E. coli suggested that BLBLI are not inferior to carbapenems in terms of 1236 
mortality and hospital stay (Rodríguez-Baño 2012). However, since the most frequent 1237 
sources of BSI in this latter study were the urinary and biliary tract, these results should 1238 
not be applied to other sources until more data are available (Retamar 213). A recent 1239 
meta-analysis did not find that carbapenems were superior to BLBLI, but the results 1240 
were limited by the quality of most of the studies included. A randomized trial 1241 
comparing piperacillin-tazobactam and meropenem is currently ongoing in Australia 1242 
and New Zealand (MERINO trial). 1243 
Temocillin, a β-lactam that is stable against ESBL and pAmpC enzymes, but is 1244 
commercialized in only a few countries, is a very interesting agent that has shown good 1245 
results in uncontrolled studies (Balakrishnan 2011) and would certainly be worthy of 1246 
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investigation in a randomized trial. Some cephalosporins, particularly ceftazidime and 1247 
cefepime, are active against ESBL-producers according to current EUCAST breakpoints 1248 
(Leclercq 2013), but clinical data in severe infections are lacking. Urinary tract 1249 
infections may be treated with aminoglycosides when active in vitro. There is limited 1250 
specific experience with tigecycline for ESBL-producers (Vasilev 2008), but this drug 1251 
has been associated with worse outcomes than comparators in different types of 1252 
infections (Tasina 2011). Colistin is usually reserved for extensively-drug resistant 1253 
isolates. Finally, fosfomycin is now being compared to meropenem for the treatment of 1254 
bacteremic UTIs in an ongoing randomised controlled trial (FOREST trial). 1255 
From a practical point of view, empirical therapy of infections potentially caused by E. 1256 
coli should include coverage against ESBL-producers according to the local 1257 
epidemiology, individual risk factors, and the severity of the infection. Some predictive 1258 
scores have been defined including age, a Charlson score >4, recent hospitalization or 1259 
hospital transfer, recent use of fluoroquinolones or cephalosporins, and recent urinary 1260 
catheterization (Tumbarello 2011; Johnson 2013). According to local susceptibility 1261 
profiles, empirical therapy may be administered with a carbapenem, or with the 1262 
combination of a cephalosporin, BLBLI or fluoroquinoline plus an aminoglycoside. 1263 
According to data currently available, de-escalation to a BLBLI may be possible 1264 
particularly in urinary or biliary tract infections. 1265 
Oral fosfomycin trometamol (Pullukcu 2007; Rodríguez-Baño 2008), amoxicillin-1266 
clavulanic acid (Rodríguez-Baño 2008) and pivmecillinam (Jansaker 2014) have shown 1267 
good results for the treatment of cystitis in observational studies. Nitrofuraintoin is also 1268 
frequently active against ESBL-producers and is, therefore, another option. 1269 
 1270 
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Therapy of carbapenemase-producers. The production of carbapenemases 1271 
dramatically reduces the therapeutic options. Carbapenemases are more frequently 1272 
found in K. pneumoniae, but may also be found in E. coli. The potential therapeutic 1273 
options depend on the type of carbapenemase; thus, aztreonam are usually active against 1274 
metallo-β-lactamases (MBL), and cephalosporins are usually active against OXA-48-1275 
producers unless an ESBL or AmpC is co-produced (which unfortunately is frequent).  1276 
KPC-producers are frequently resistant to all β-lactams. The most frequently active 1277 
options against carbapenemase-producers are colistin, tigecyline, and fosfomycin, and 1278 
in some cases, aminoglycosides (Tzouvelekis 2012).  1279 
The evidence available to provide recommendations for therapy is limited to some 1280 
observational studies mainly including KPC (Zarkotou 2011; Tumbarello 2012; 1281 
Gonzalez-Padilla 2014) or OXA-48 (Navarro-San Francisco 2013; Balkan 2014) 1282 
producing K. pneumoniae. Data with aztreonam for MBL-producers or cephalosporins 1283 
for OXA-48 producers are lacking. The results of some of the previous studies 1284 
(Tumbarello 2012) have suggested that combination therapy in severe infections may be 1285 
superior to monotherapy probably because the most active drugs are less effective, 1286 
“second-line” antibiotics. In addition, pharmacokinetic and pharmacodynamics data and 1287 
some observational studies have suggested that a carbapenem should be part of the 1288 
combination regimen if the MIC of the isolate is ≤8 (or even 16) mg/L and the 1289 
carbapenem should be used at optimised doses so that sufficient concentrations can be 1290 
reached (e.g., meropenem 2 g every 8 hours in prolonged infusion) (Tumbarello 2012). 1291 
However, the superiority of combination therapy is controversial because of the 1292 
limitations of the previous studies and the results of a meta-analysis of studies on 1293 
carbapenem-resistant Gram-negative bacteria (Paul 2014). Since the use of combination 1294 
therapy is not without problems, decisions must be made on an individual basis 1295 
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considering the options available, the source, and the severity of the infection. It is our 1296 
opinion that combination therapy is not needed in most cases of mild to moderate 1297 
infections, in UTIs or when the source can be readily removed. 1298 
 1299 
Plasticity of the Escherichia coli Genome: Can We Define Specific Pathotypes? 1300 
The term bacterial “pathogenicity” is usually understood as the capability of certain 1301 
bacterial organisms to produce diseases, in general infections, in humans or animals. 1302 
Along the last decades, the predominant idea supporting research on the pathogenicity 1303 
of E. coli (the same applies to other microbes) is that a number of basically innocent 1304 
commensal E. coli lineages have acquired a number of genetic traits which convert them 1305 
into nasty, pathogenic organisms. The microecological features shaping this conversion 1306 
should be characterized to understand how a useful commensal can become a harmful 1307 
pathogen (Tenaillon 2010). “Specific” genetic traits of pathogens are generally known 1308 
as “pathogenicity factors” and have been identified because of their association with the 1309 
production of acquired genetic elements encoding toxins, and in more recent times, as 1310 
the products encoded by genes that when disturbed (for instance by random 1311 
transposition) strongly reduce the pathogenicity in suitable animal models. In the first 1312 
case, “pathogenicity” is clearly acquired; in the second, we address the “intrinsic” (or 1313 
acquired a long time ago) pathogenic factors. When we refer to “specific pathotypes” 1314 
we focus on the E. coli groups known as EPEC, EHEC, STEC, ETEC, EAEC, DAEC, 1315 
and EIEC. In most or all of these cases, intestinal pathogenicity is addressed, and 1316 
depends on particular, well-defined acquired traits.  What is much less clear is whether 1317 
E. coli “specific pathotypes” can be considered: UPEC (uropathogenic) NMEC 1318 
(neonatal meningitis) and ExPEC (extraintestinal pathogenic). In fact, the variety of E. 1319 
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coli producing UTIs or bloodstream infections is extremely large. It is true that some 1320 
particular clones are (currently) frequent in these conditions, but whether they constitute 1321 
a specific “pathotype group” is highly debatable. In fact, it is difficult to maintain the 1322 
hypothesis of a sustained genetic adaptation of E. coli organisms to non-permanent 1323 
stressful niches such as urine, deep tissues, or blood which are far from those that have 1324 
shaped their lifestyle and evolutionary history. 1325 
We have recently reconsidered the phylogenetic structure of E. coli in a well-pondered 1326 
collection of 128 strains of different origins, using a 5,384 bp concatenated sequence of 1327 
full MLST genes (adk, fumC, icd, mdh, purA, recA, and gyrB). This technique provides 1328 
highly comparable results to those obtained by considering all core genes in the E. coli 1329 
genome (data not shown) and allowed the clear identification of the recently recognized 1330 
phylogenetic structure in seven lineages (A, B1, B2, C, D, E, F). Using the Neighbour 1331 
Net algorithm in SplitsTree v.4., and overprinting the concatenated trees of each of the 1332 
individual MLST genes to the basic phylogenetic tree, genetic interactions between 1333 
lineages (recombinatorial events) were easily detected. The B2 phylogroup appeared 1334 
distantly located from the other phylogroups and showed the lowest intergroup 1335 
recombination frequencies (1.6%), while B1 phylogroup was highly recombinant 1336 
(17.7%). Groups A (9.7 %), and D (10.2 %) recombination frequencies were lower than 1337 
those of groups C (12.4) and F (28.6%).  Groups C, E, and F have probably emerged in 1338 
relatively modern times by recombination between other phylogenetic lineages; for 1339 
instance, phylogroup C arises from groups A and B1, and phylogroup F maintain 1340 
promiscuous interactions with group D, suggesting a common ancestor. In summary, 1341 
phylogroup B2 has almost exclusively intracladed recombination, whereas strains of the 1342 
phylogroups A, B1, and C show the highest rate of homoplasy (Turrientes 2014). 1343 
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How are “pathogenic lineages” (pathotypes, pathovars) distributed in these main 1344 
branches of the phylogenetic tree? Current data suggests that those associated with 1345 
milder and chronic diarrhea, such as EAEC and DAEC, are found throughout the tree, 1346 
while those producing more severe intestinal diseases, such as EHEC, ETEC, and 1347 
Shigella/EIEC, are more frequently found dispersed in the A, B1, C, and E 1348 
“commensal” phylogroups, and EPEC is more frequent in the B1 and B2 phylogroups 1349 
(Chaudhuri 2012). In general, it is difficult to trace long term “pathogenic lineages”, in 1350 
the same way that it is difficult to trace long-term “extended-spectrum beta-lactamase 1351 
producers”. The higher prevalence in some lineages might exclusively reflect the bias 1352 
produced by epidemic events. 1353 
As far as bacteremic strains are concerned, can any extraintestinal pathogenic E. coli 1354 
(ExPEC) “pathotype” be recognized among these isolates? In the first publications 1355 
about ExPEC, these strains were considered as “specialized strains” possessing a unique 1356 
ability to cause disease outside the host intestinal tract (Johnson 2002a). Does ExPEC 1357 
belong to specific phylogenetic lineages? In a series of 528 blood isolates recovered  at  1358 
Ramón y Cajal Hospital along the last 17 years, these “ExPEC” were predominantly 1359 
phylogroup B2 (54%), followed by phylogroups D/E/F (21%), A/C (16%), and B1 1360 
(9%).This means that a variety of phylogroups are also associated with bacteremia, 1361 
including those that are considered to group commensal intestinal strains. We postulate 1362 
that any kind of E. coli might produce bacteremia as a result of stochastic events (like 1363 
translocation), probably facilitated by a large intestinal population abundance 1364 
(colonization density), and host factors (such as underlying diseases, and ageing), so 1365 
that there is a thin line between commensalism and pathogenicity (Leimbach 2013).  1366 
In general, we agree with the concept that so-called ExPEC are facultative pathogens 1367 
which belong to the normal gut flora of a certain fraction of the healthy population 1368 
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where they live as commensals (Köhler 2011). However, it remains plausible that some 1369 
particular E. coli clones, more frequently in phylogroup B2, are more prone than others 1370 
to cause bacteremia, but of course, they cannot be considered as having a deterministic 1371 
causation for extraintestinal diseases, that is, they cannot be considered as belonging to 1372 
a specific pathotype. The successful spread of these clones (and the clones derived from 1373 
them) might increase the incidence of bacteremic episodes. Pathogenicity is frequently 1374 
associated with comparatively smaller population sizes but higher transmission abilities 1375 
(smaller propagulum). In our hospital, a progressive but significant increase in the 1376 
number of bacteremic isolates has been observed along the last decade, from 450-500 1377 
isolates per year in 1996-2002, to 600-750 isolates per year in 2002-2012. This increase 1378 
can be partially attributed to a group of clones of the phylogroup B2, most being ST131 1379 
or their derived variants. In fact, the B2 non-ST131 bacteremic strains have remained 1380 
fairly constant along the last 17 years.  1381 
The reason why the phylogroup B2 (at large) is more frequent than other phylogroups 1382 
among bacteremic isolates is an interesting case for evolutionary biologists. Is there a 1383 
link between evolutionary history of E. coli and its propensity for invasive infections? 1384 
Human E. coli strains have evolved from those colonizing mammalian ancestors. 1385 
Probably the first E. coli strains in these early lineages, before the divergence of the 1386 
great apes (≥30 million of years ago) were from the B2 and D phylogroups, probably 1387 
derived from avian pathogenic E. coli (APEC). Species-to-species transition is a hard 1388 
venture. Novel organisms should compete with the already established microbial 1389 
populations filling all the available niches, but the “more pathogenic clones” (such as 1390 
those of phylogroups B2 and D) have the possibility of opening new niches by 1391 
obtaining resources from the host. As is frequent in the evolution of pathogenesis, less 1392 
pathogenic variants tend to emerge from the more aggressive variants, assuring long-1393 
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term coexistence with the host, presumptively leading to phylogroups A, B1, C, and E 1394 
probably 20-25 million years ago (Escobar-Páramo 2003; Parsot 2008; Touchon 2009). 1395 
The success of these phylogroups as commensals (in different animals!) maintained the 1396 
old phylogroups B2 and D in their more “pathogenic” niches. In bacterial evolution, the 1397 
ancestor lineages are not necessarily replaced by the derived lineages, probably because 1398 
of the frequent multiplicity of available hosts and microniches. The emergence of the 1399 
highly pathogenic E. coli group known as Shigella occurred accidentally less than 5 1400 
million years ago (30 000 years ago?) by the acquisition of foreign genetic material (via 1401 
mobile genetic elements) in commensal E. coli groups. Note that inside phylogroup B2 1402 
some clones are particularly prone to cause extraintestinal infections, such as O25-1403 
ST131 E. coli. These highly transmissible clones have recently spread, increased their 1404 
exposure to antimicrobial drugs, acquired antibiotic resistance mechanisms, and 1405 
selected by the use of antibiotics in therapy. Host-to-host transmission has produced a 1406 
diversifying selection effect, so that currently at least three clusters of different PFGE-1407 
types can be recognized among our blood isolates. One of the drivers for such 1408 
diversification is probably the sequential acquisition of fluoroquinolone, and then 1409 
extended-spectrum beta-lactamases, so that the originally susceptible population was 1410 
reduced in frequency, and the overall proportion of O25-ST131 was increased in blood 1411 
isolates. Another diversifying driver is the high “internal recombination” among 1412 
phylogroup B2 clones, constantly providing genetic combinations offered to natural 1413 
selection. 1414 
 1415 
CONCLUDING REMARKS 1416 
Page 60 of 107
ScholarOne Support 1-434/964-4100
FEMS Microbiology Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
60 
 
Extraintestinal E. coli infections, which represent a major public health problem, are 1417 
caused mainly by specialized ExPEC strains that can innocuously colonize human hosts 1418 
but also cause disease upon entering a normally sterile body site. The virulence 1419 
capability of such strains is determined by their combination of distinctive accessory 1420 
traits, called virulence factors, in conjunction with their distinctive phylogenetic 1421 
background. It is conceivable that by developing interventions against the most 1422 
successful ExPEC lineages or their key virulence/colonization factors in the future it 1423 
will be possible to reduce the associated burden of disease and health care costs. 1424 
The evolution of resistance plasmids clearly shows that these mobile elements 1425 
accumulate a series of antibiotic resistance determinants, thus making these plasmids 1426 
extremely threatening. Not only do they encode multidrug resistance, but indeed, they 1427 
can be easily selected by many different selective agents. It is important to mention that 1428 
successful plasmids possess great versatility to intracellular adaptation by the presence 1429 
of addiction systems (toxin-antitoxin, restriction enzymes) and partitioning proteins that 1430 
promote plasmid maintenance during vertical transmission in the daughter cells. These 1431 
plasmids are very stable in their bacterial host and this characteristic certainly influences 1432 
their success, independently by antimicrobial resistance and other factors that can 1433 
positively select these molecules. 1434 
Therapy of multidrug-resistant E. coli is increasingly challenging. Therapeutic decisions 1435 
are important not only for the individual patient but also for avoiding further selection 1436 
pressure. Randomized controlled trials and high quality observational studies are 1437 
urgently needed for therapeutic decision making, which must now be undertaken on an 1438 
individual basis. Some promising new drugs are being investigated, including the β-1439 
lactamase inhibitor avibactam (in combination with ceftaroline and aztreonam), 1440 
ceftolozone-tazobactam, plazomicin and omadacyclin. 1441 
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In conclusion, the definition of specific extraintestinal pathotypes in E. coli remains 1442 
obscure. Organisms of particular phylogroups are more or less prone to evolve by 1443 
acquisition of particular virulence traits, often in a highly unpredictable way (Baquero 1444 
2013). However, this probabilistic view is insufficient to make any strong causal 1445 
association of specific lineages (beyond specific clones) with particular infectious 1446 
diseases.    1447 
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FIGURE LEGENDS 
Figure 1. Rdar colony morphology type of E. coli Nissle 1917 on Yesca medium agar 
plates at 28°C (left) and 37°C (right). 
Figure 2. Adherence of E. coli UEB1r and its csgD deletion mutant to silicon-elastomer 
coated foley catheter surface. Photo: Heinrich Lünsdorf; experiment Xiaoda Wang, PhD 
thesis. 
Figure 3. Resistance rates in E. coli isolates reported until April 2013 in different 
geographic areas. 
3-CG, third generation cephalosporin; FQ, fluoroquinolone 
 
Figure 4. Third generation cephalosporin resistance found in the SMART study. 
 
Figure 5. Major structural features of the IncN plasmids, pQNR2078 and pNL194, the 
IncF plasmids, pC15-15 and pEK516, and the IncA/C plasmid, pNDM-KN. 
The tra locus is indicated by green arrows. Resistance genes are indicated by red boxes, 
except for the blaNDM-1 gene that is indicated by a blue box. Transposon-related genes 
[tnpA, tnpR, tnpM] and insertion sequences are indicated by yellow boxes. Other genes 
are indicated by colored boxes as follows: violet, replicase gene repA; orange, 
restriction enzyme and DNA methylase genes; white, other plasmid genes.   
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Figure 1. Highest resistance rates reported in E. coli isolates reported until April 2013 
in different geographic areas. (WHO, 2014) 
 
 
 
3-CG, third generation cephalosporin;  FQ, fluoroquinolone 
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Figure 2. Third generation cephalosporin resistance in E. coli obtain from 
intraabdomial infections found in the SMART study (111). 
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Table 1. Studies about GBS and E. coli prevalence before and after intra-amniotic 
prophylaxis. 
Reference
GBS E. coli GBS E. coli
Levine et al. (1999) 1.7/1,000 0.29/1,000 0 1.3/1,000
Stoll et al. (2002) 5.9/1,000 3.2/1,000 1.7/1,000 6.8/1,000
Daley et al. (2004) 1.43/1,000 0.32/1,000 0.25/1,000 no change
Lopez-Sastre et al. (2005) 1.10/1,000 0.17/1,000 0.7/1,000 0.38/1,000
Schrag et al. (2006) 1.7/1,000 3.2/1,000 0.34/1,000 6.8/1,000
van den Hoohen et al. (2010) 1.8% 1% 0.7% 0.3%
Lin  et al. (2012) 45.4% 40.9% 20% 70%
Before IAP After IAP
 
 
IAP, intra-amniotic prophylaxis. 
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Table 2. Mechanisms of resistance to quinolone in Escherichia coli 
 
1. Chromosomal-mediated 
- Changes in protein targets 
o Mutations in the gyrA gene (amino acid codon Ser-83 and 
Asp-87) 
o Mutations in the parC gene (amino acid codon Ser-80 and 
Glu-84) 
- Reduction in the accumulation of the quinolone* 
o Decrease in permeability – Decreased expression of OmpF 
o Increase in active efflux systems: 
 AcrAB, AcrEF 
 MdfA 
 YdhE 
 
2. Plasmid-mediated 
-       DNA gyrase and topoisomerase IV protection from quinolone 
inhibition  -  Qnr 
-       Aminoglycoside-acetyltransferase – AAC(6’)-Ib-cr 
-       Efflux pumps: 
 QepA 
 OqxAB 
______________________________________________________________________ 
* Transcriptional factors such as MarA can concomitantly regulate the expression of 
OmpF and AcrAB-TolC 
 
Page 107 of 107
ScholarOne Support 1-434/964-4100
FEMS Microbiology Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
